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ABSTRACT 
Expression of Notch Signaling Pathway Receptors and Ligands in 
 Human Breast Cancer Cell Lines and Human Breast Tumors 
 
Özden Yalçın 
M.Sc. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Mehmet ÖZTÜRK 
September 2004, 69 pages 
Breast cancer is the most common cancer type in women. Traditional therapies 
targeting proliferating cells cannot be effective in all cases and recursion is observed 
in 40% of breast cancers within 10 years. One possible explanation is that the origin 
of breast cancer is ‘breast cancer stem cells’, which cannot be killed by these 
therapies. Cancer stem cells are thought to be formed due to deregulation of normal 
stem cells. Breast tissue also contains normal stem cells required for its development 
during puberty and pregnancy; and putative breast cancer stem cells have recently 
been isolated. Investigation of pathways used in stem cell regulation is the first step 
to understand the contribution of stem cells to tumorgenesis and design new 
therapeutic approaches. Notch signaling is involved in stem cell maintenance and 
many types of human cancers. Notch activation in mouse mammary gland 
development and tumorigenesis lead us to its possible role in human mammary gland 
tumorigenesis. The expression of Notch receptors and ligands were identified by 
semi-quantitative RT-PCR in human breast cancer cell lines and tumor samples. It 
was found that Notch3 expression was strongly upregulated in cancer cells lines and 
tumors compared to normal cell line, while other receptors and ligands did not have 
significant changes in expression. Depending on the upregulation of Notch3 
expression in putative breast stem cells, we may hypothesize that its activation keeps 
cells in a stem cell like phenotype, inhibit differentiation and increase cancer risk.     
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ÖZET 
İnsan Meme Kanseri Hücre Hatlarında ve Meme Tümörlerinde  
Notch Yolağı Reseptör ve Ligandlarının Ekspresyonu  
 
Özden Yalçın 
Yüksek Lisans Tezi, Moleküler Biyoloji ve Genetik Bölümü  
Tez Yöneticisi: Prof. Dr. Mehmet ÖZTÜRK 
Eylül 2004, 69 sayfa 
Meme kanseri kadınlar arasında en sık görülen kanser türüdür. Çoğalan hücreleri 
hedefleyen geleneksel tedavi yöntemleri her durumda etkili olamamakta ve meme 
kanserlerinin %40’ı 10 yıl içinde tekrarlamaktadır. Meme kanserinin temelinde bu 
tedavi yöntemleriyle yok edilemeyen ‘meme kanseri kök hücreleri’nin olması bu 
duruma bir açıklama getirebilir. Kanser kök hücrelerinin, normal kök hücrelerin 
kontrolünün bozulması sonucunda ortaya çıktığı düşünülmektedir. Meme dokusu, 
ergenlik ve hamilelik sırasındaki gelişimi için gereken normal kök hücreler 
içermektedir, ve muhtemel meme kanseri kök hücreleri de yakın zaman önce 
ayrıştırılmıştır. Kök hücre kontrolünde görev yapan yolakların araştırılması, kök 
hücrelerin tümör oluşumuna katılımını anlamak ve yeni tedavi yöntemleri 
geliştirmek için gereken ilk adım olmalıdır. Notch yolağı, kök hücrelerin 
devamlılığında ve insanlarda bazı kanser türlerinde önemli bir role sahiptir. Farede 
meme dokusu gelişiminde ve tümör oluşumundaki aktivasyonu, Notch yolağının 
insanda da meme kanserinde bir rolü olabileceği sonucuna ulaştırmıştır. İnsan meme 
kanseri hücre hatları ve meme tümörlerinde Notch reseptör ve ligandlarının 
ekspresyonu yarı-nicel RT-PCR yöntemi ile belirlenmiştir. Diğer reseptör ve 
ligandların ekspresyonunda anlamlı bir değişiklik gözlenemezken, Notch3 
ekspresyonunun, meme kanseri hücre hatları ve tümörlerinde normal hücre hattına 
göre arttığı saptanmıştır. Muhtemel meme kök höcrelerinde ekspresyonunun arttığı 
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göz önünde bulundurulursa, Notch3 aktivasyonunun hücreleri kök hücre fenotipinde 
tutup farklılaşmayı önleyerek kanser riskini artırdığı hipotezini ortaya koyabiliriz. 
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CHAPTER 1      INTRODUCTION 
The expression patterns of Notch receptors and ligands in breast cancer cell 
lines and human breast tumors are presented in this study. Before introducing the 
project, the literature will be reviewed in order to focus on some of the basic 
concepts about breast cancer and Notch signaling. First, development of breast and 
then breast cancer will be reviewed. Next, the current studies related to stem cells 
and cancer will be summarized. Then, specifically breast stem cells will be 
presented. Finally, Notch signaling and its relation to breast cancer will be 
introduced.    
1.1 Development of Breast 
The four main structures in an adult human breast are lobules, ducts, fat and 
connective tissue (Figure 1.1). “Nipple” surrounded by the dark tissue “areola”, is the 
protruding point of the breast. “Lobes” are composed of lobules or glands, which are 
the milk producing parts during lactation. “Ducts” are the branching tubes that are 
connected to lobes, and converge to the larger “collecting ducts” towards the nipple. 
Ducts are responsible for carrying the milk from lobes to nipple during lactation. The 
branching ductal system and alveoli are supported by stroma, which is consists of fat 
and connective tissue, blood and lymphatic vessels (www.mammary.nih.gova).  
 2
 
Figure 1.1 Structures of human breast. (www.mammary.nih.gova)  
Breast tissue, in contrast to most mammalian organs, is found at a 
rudimentary state after birth, and completes its maturation during puberty. In human 
embryo, breast begins to develop at around weeks 7 to 8, and visible structures are 
observed at around weeks 12 to 16 (www.mammary.nih.gova). The breast tissue is 
originated from ectoderm. First detectable structure called milk line, mammary crest 
or mammary band is a thickening extending across the embryo in a region, where 
breast bud will form. The first nipple is observed when the embryo is around 7-8mm 
length, it is seen as a narrow collection of ectodermal cells. Around 10mm length, the 
cells have a close relation with mesenchyme. Actually, the mesenchymal-epithelial 
interactions direct the breast development in embryo. Around day 14, following the 
differentiation of mesenchyme, epithelia proliferate to form a nodule that pushes 
mesencyme. The nodule then forms the breast bud. The bud starts to branch and form 
secondary buds with a clover-shape. Then secondary buds form canals and branch. 
The ductal morphogenesis in embryo is achieved by elongation and invasion of 
branches into the mesenchyme. Both female and male breast tissue shows the same 
development in embryo (Howard and Gusterson, 2000).  
At birth, ductal system opens to the surface through a cavity on skin. The 
underlying mesenchyme proliferates to form nipple, and skin surrounding the nipple 
proliferates to form areola. The stage of breast development at birth differs from 
individual to individual. Some babies may have only small blunt ended tubular 
structures, while others may have well-developed branches. Both male and female 
babies may secrete some milk in response to maternal hormones. And during first 
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two years the lining epithelium proliferates and then involutes upon removal of the 
maternal hormones` effects. At the end of two years, only small ductal structures 
remain in a fibroblastic stroma and this state is kept until puberty (Howard and 
Gusterson, 2000). 
Upon hormone stimulation with the beginning of the puberty, the breast 
structure further develops. The anatomical changes at this stage is well established, 
however the cellular events are not well understood. During this stage, in addition to 
epithelium, stroma also changes. Fibrous and fatty tissue increases that in a non-
lactating breast it constitutes around 80% of the tissue. Hormones stimulate the 
growth of ducts, invasion into the fat pads and formation of lobular structures. The 
growing part of the tissue is “terminal end buds” (TEB), which consist of “body cell” 
mass surrounded by a layer of “cap cells”. Body cells are thought to form inner 
“luminal epithelial cells”, which lines the lumen. Cap cells are thought to form the 
outer “myoepithelial cells”, which are contractile cells found around the secretory 
alveoli cells and ducts; and cause squeezing the milk down to the ducts and then out 
of nipple upon oxytocin stimulation. Upon reaching the borders of fat pad, branching 
is completed and TEBs disappear (Howard and Gusterson, 2000; Smalley and 
Ashworth, 2003). 
Human breast during pregnancy and lactation could not be studied well. In 
general, an increase in the number of lobules and loss of fat is observed. Lobulo-
acinar structures, which have milk-secreting alveolar cells, are formed due to high 
proliferation followed by terminal differentiation. At weaning, removal of suckling 
stimulus results in involution, which means elimination of secretory epithelial cells 
by apoptosis and phagocytosis. At each pregnancy Terminal Duct Lobular Units 
(TDLUs) expand in size and then involutes. The ducts are not changed during this 
process. At menopause, a greater involution occurs for both lobules and ducts. The 
removed epithelium and interlobular connective tissue are replaced by fat (Howard 
and Gusterson, 2000). 
It is not easy to study breast in humans. The similarities between mouse and 
human mammary gland development and function make mouse a good model. We 
have more detailed information about these processes in mice and that help us to 
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understand the mammary gland better. The figure below shows the dramatic changes 
of mouse mammary gland at different stages of development (Figure 1.2). Similar to 
development in human, mouse mammary gland development begins with thickening 
of epithelial cells and running from anterior to posterior direction in the embryo. The 
mammary bud forms and invades the mesenchyme, then encounters secondary 
mesenchyme, which is the precursor of mammary fat pad. The interactions with the 
mesenchyme induce a small amount of branching and form a rudimentary gland that 
remains unchanged till puberty. At puberty, hormones stimulate rapid elongation and 
branching by TEB similar to human. The ductal elongation ceases when the ducts 
reach to the periphery of the fat pad (Figure 1.2.c and 1.2.d), and the gland remain at 
this stage until pregnancy. The process from embryo to adult virgin animal can be 
called as “linear phase” of the mammary gland development (Lewis, 2000).  
 
Figure 1.2 Stages of mouse mammary gland development. a. 3 weeks old mouse 
with slowly elongating and branching ducts. b. 4 weeks old virgin mouse with 
significantly increased growth of ducts around lymph node. c. 6 weeks old virgin 
mouse has ducts that reached to the periphery of mammary fat pad. d. 10 weeks old 
virgin mouse has ducts that completely reached to the periphery of mammary fat pad. 
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The ductal development decreases at that time. e. Day 9 pregnant mouse with an 
extensive and rapid proliferation of mammary ducts. f. Day 16 pregnant mouse has 
an expanded mammary epithelium (www.mammary.nih.govb). 
Pregnancy initiates the “cyclical phase” of the development, which is 
repeated in each pregnancy. The morphology of breast changes from ductal to 
lobuloalveolar structure (Figure 1.3). The progenitor cells proliferate and 
differentiate to form the alveolar buds and then alveoli. Alveolar cells gain capacity 
to express milk proteins at the middle of the pregnancy but secretion is inhibited until 
delivery. Weaning terminates the milk secretion and involution occurs by apoptosis. 
The gland returns to ductal morphology until next pregnancy, in which the same 
cycle is repeated (Lewis, 2000). 
 
 
Figure 1.3 Cyclical phase of mouse mammary gland development. The 
predominant ductal and lobuloalveolar morphology are seen in virgin and pregnant 
mouse respectively. The extensively condensed milk secreting lobuloalveolar cells in 
lactating mouse collapsed during involution by apoptosis (www.mammary.nih.govb).  
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1.2 Breast Cancer  
1.2.1  Epidemiology of Breast Cancer 
Cancer is the second leading cause of death in U.S., and constitutes for the 
one fourth of all deaths. In 2004, 1,363,030 new diagnoses and 563,700 cancer 
deaths are expected to occur in U.S. Breast cancer is one of the important cancer 
types that it is the most frequently diagnosed non-skin cancer in women. 215,990 
new invasive breast cancer cases, which is 32% of total, are expected to be diagnosed 
in women, in 2004. Breast cancer is the second for cancer deaths in women after lung 
cancer in U.S. 40,110 women, which is 15% of total, are expected to die because of 
breast cancer in 2004. In addition to invasive breast cancer, 59,390 women are 
expected to be diagnosed with in situ breast cancer. The number of males affected 
from breast cancer is not very low that the expected new diagnosis of and deaths 
from breast cancer is 1,450 and 470 respectively in males, in 2004. According to 
World Health Organization, 1.2 million people will be diagnosed with breast cancer 
worldwide (www.imaginis.com, American Cancer Society, 2004).  
In Turkey, the facts about breast cancer are similar to U.S. According to 1999 
statistics of Turkish Ministry of Health, breast cancer is the most common cancer 
followed by stomach cancer in Turkish women with 2,390 cases that makes 24.1% of 
all cancers in women. 
According to statistics, breast cancer risk increases by age, 94% of new 
diagnosed cases and 96% of deaths occur after age 40 (American Cancer Society, 
2003-2004). The menstrual history is also important that early onset and long period 
of menstruation, and menopause at older ages increases breast cancer risk. Although 
non-proliferative benign breast diseases has a very little or no effect on cancer risk, 
proliferative lesions without atypia and atypical hyperplasia increase breast cancer 
risk about two or four fold, respectively. Alcohol consumption is directly 
proportional to breast cancer risk that 10gr of alcohol per day increases the risk by 
10% (Smith-Warner et al., 1998). Ionizing radiation and personal or familial history 
of breast cancer definitely increases breast cancer risk (Key et al., 2001). 
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Breast cancer risk increases immediately after the birth; however in long term 
childbearing has a protective effect. In addition, the high number of pregnancies and 
having the first child at an earlier age decreases risk significantly. The risk for the 
women with five or more children is half of the risk for the women without any child 
(Layde et al., 1989; Ewertz et al., 1990). The younger age at first birth has a 
protective effect that the women, who had first child earlier than age 20 has 30% 
lower risk compared to women, who had after 35 (Ewertz et al., 1990). 
Breastfeeding, experiencing menopause earlier, low-fat diet, a moderate physical 
activity and a healthy body weight are other factors decreasing the breast cancer risk 
(Key et al., 2001; American Cancer Society, 2004).  
1.2.2 Histology of Breast Cancer 
Most of tumors detected in breast are benign that they do not spread and 
become life threatening (American Cancer Society, 2003-2004). Breast carcinomas 
are originated from the malignant transformation of ductal or lobular epithelial cells. 
Normal epithelial cells may progressively develop ductal hyperplasia, atypical ductal 
hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma and then metastasis, 
or they may directly form in situ or invasive type of breast cancer (Vogelstein and 
Kinzler, 1998; Russo et al., 1998). 
In situ type of breast cancer indicates the early stages of breast cancer, these 
tumors are cancerous but they do not spread beyond the regions they originated and 
almost all cases can be cured.  
1.2.2.1 Ductal Carcinoma in Situ 
Ductal carcinoma in situ (DCIS) is the most common noninvasive breast 
cancer that constitutes 85% of all in situ breast cancers. The increased rate of 
incidence is due to early detection by mammography screening. The epithelial cells 
of ducts form the tumor but the tumor does not spread beyond the duct walls through 
the surrounding stroma (American Cancer Society, 2003-2004; www.cancer.orga).  
DCIS is thought to be the precursor of invasive breast carcinoma. After 
removal of the DCIS lesions, 30-50% of patients developed invasive breast cancer in 
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6-10 years at the same site of previous DCIS (Page et al., 1982; Rosen et al., 1980). 
Basically DCIS is subdivided into two classes called comedo and non-comedo. 
Comedo type includes dead cells, and necrosis inside the tumor, and it is more 
malignant that precedes invasion (DeVita et al., 2001). Comedo type DCIS lesions 
usually lack estrogen and progesterone receptors (Albonico et al., 1998), overexpress 
oncogene c-erbB-2 and have mutated p53 accumulation (Poller et al., 1993; 
O’Malley et al., 1994). Angiogenesis is observed in the stroma surrounding the 
comedo DCIS lesions (Engels et al., 1997).  
1.2.2.2 Lobular Carcinoma in Situ 
Lobular carcinoma in situ (LCIS) is a less common type of noninvasive in 
situ breast cancers. It is originated from the lobules but not spread beyond them 
(American Cancer Society, 2003-2004; www.cancer.orga). 
LCIS cannot be detected by physical examination or mammography; it is 
usually detected in the tissues removed for other reasons. LCIS is a homogeneous 
mass consist of small cells containing small and rounded-oval nuclei. The most 
characteristic pattern of LCIS is the loss of e-cadherin protein (Vos et al., 1997). The 
women, who had LCIS have a 7-10 times more risk for developing breast carcinoma.  
(Vogelstein and Kinzler, 1998; DeVita et al., 2001). 
1.2.2.3 Invasive Breast Cancer 
Infiltrating (invasive) breast cancer starts in lobules or ducts and invades the 
surrounding tissue. There are three stages of invasive breast cancer; in local stage 
tumor is fixed to the breast, in regional stage tumor spread to surrounding tissue or 
nearby lymph nodes, and in distant stage tumor metastasized to distant organs 
(American Cancer Society, 2003-2004; www.cancer.orga).  
‘Infiltrating (invasive) ductal carcinoma’ (IDC) is the most common type of 
breast cancer, covering around 80% of all invasive breast cancers. It is originated in 
the ducts and spread beyond the duct wall invading the fatty tissue. ‘Infiltrating 
(invasive) lobular carcinoma’ (ILC) is originated from lobules and it is a less 
common type. Both invasive carcinomas can metastasize to other parts of body via 
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blood and lymphatic vessels. The other rare types of invasive breast cancer includes 
‘tubular carcinoma’, in which tubules are formed; ‘medullary carcinoma’ consists of 
poorly differentiated and large cells, and have immune system cells around the tumor 
tissue; ‘mucinous (colloid) carcinoma’, which is characterized by the accumulation 
of extracellular mucus. The prognoses for these three types are better than IDC and 
ILC. Another rare type of invasive breast cancer is ‘inflammatory breast cancer’, 
which results in a red and pitted appearance of breast due to the blocking of 
lymphatic vessels or channels in the skin (Vogelstein and Kinzler, 1998; 
www.cancer.orga).  
The prognosis and treatment strategy are directly related to the stage of the 
invasive breast cancer. The most commonly used staging system is the TNM system 
stated by American Joint Committee on Cancer. The three main criteria are the size 
and spreading in breast or nearby organs indicated by ‘T’, spreading to the lymph 
nodes indicated by ‘N’, and metastasis indicated by ‘M’. The evaluation of T, N and 
M stages gives the general stage of patient from stage I (the least advanced) to the 
stage IV (the worst case) (www.cancer.orgb) . 
Several therapies including surgery, radiation therapy, chemotherapy, 
hormone or antibody therapy are applied to breast cancer in combination. Depending 
on the tumor type surgery can be applied in different ways. Lumpectomy is the local 
removal of tumor and a part of surrounding tissue. Mastectomy is removal of entire 
breast, and modified radical mastectomy is the removal of lymph node under arm in 
addition to entire breast. Surgery is usually followed by radiation therapy or 
chemotherapy together with hormone therapy, in order to destroy undetectable 
remaining tumor cells. Tamoxifen is one of the commonly used anti-estrogen drugs. 
Also some drugs interfering with estrogen synthesizing enzyme are used. These 
therapies can also be applied before surgery to reduce the size of tumor.  (American 
Cancer Society, 2003-2004). 
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1.2.3 Molecular Biology of Breast Cancer 
1.2.3.1 Germ Line Mutations in Breast Cancer 
BRCA-1 and BRCA-2 are breast cancer susceptibility genes, which function 
as tumor suppressors and involved in the repair of damaged DNA in normal cells. 
BRCA1 and BRCA2 mutations constitute 5% of all breast cancer cases and they are 
associated with hereditary breast cancer (American Cancer Society, 2004). Female 
carriers of BRCA1 mutation have 87% life time risk for developing breast cancer and 
40-60% for ovarian cancer. Almost all mutations of this gene are germ line 
mutations, and depending on the rare somatic mutations we can conclude that 
BRCA-1 mutations do not play a major role in sporadic breast cancers in contrast to 
hereditary cases. However, in sporadic cancer cell lines abnormal cytoplasmic 
localization that it is found in nucleus in normal cells and decreased expression 
during progression of sporadic breast cancers are observed (Chen et al. 1995; 
Thompson et al., 1995). Similar to BRCA-1, BRCA-2 is not thought to have a role in 
sporadic breast cancer and female carriers of BRCA-2 mutations have 85% life time 
risk for developing breast cancer but the risk for ovarian cancer is lower (10-
20%).(Vogelstein and Kinzler, 1998; DeVita et al., 2001).  
Other germ line mutations causing breast cancer are also associated with 
other tumor types and diseases. Li-Fraumeni syndrome is a result of germ line 
mutation in TP53 gene, which in addition to breast cancer may give rise to other 
types of tumor like soft-tissue sarcomas, brain tumor, and leukemia. Cowden disease, 
increases the risk of breast cancer in addition to several different features, and carries 
PTEN mutation. MLH1, MSH2 are mutated in Muir-Torre syndrome, which 
increases the breast cancer risk and associated with skin and upper and lower 
gastrointestinal tumors. Ataxia-telangiectasia is another disease associated to breast 
cancer risk but lower than other diseases, with non-Hodgkin Lymphoma, ovarian 
cancer, stomach, pancreas and bladder malignancies. Mutations in ATM gene are 
found in Ataxia-telangiectasia (Vogelstein and Kinzler, 1998; DeVita et al., 2001). 
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1.2.3.2 Somatic Mutations in Breast Cancer 
Loss of heterozygosity (LOH) in cancers is usually involved in tumor 
suppressor genes. In breast cancer LOH is observed in some important locus 
including the genes RB-1, CDKN2, CDH1, and TP53. RB-1 and CDKN2 encode 
retinioblastoma and p16 proteins respectively, which are involved in cell cycle 
regulation. CDH1 encodes E-cadherin, which regulates differentiation and tissue 
compartmentalization. Point mutations for TP53 and RB-1 are more common, while 
methylation is mostly observed in CDKN2 and CDH1. TP53 mutations are analyzed 
in several groups of breast cancer samples and results showed that TP53 mutations 
are associated with poor prognosis. Cyclin D1, another important protein involved in 
cell cycle regulation. It was overexpressed in some of the breast cancer cell lines and 
in 45% of breast tumors in a study (Buckley et al., 1993). Increase in cyclin D1 
expression is thought to be an early event in breast cancer development. One of the 
most common gene amplifications in breast cancer occur in c-MYC gene, which is a 
protooncogene, involved in cell proliferation or apoptosis depending on the cellular 
context. However the detection of c-Myc at protein level is harder because of short 
half-life of protein (Vogelstein and Kinzler, 1998; DeVita et al., 2001). 
Epidermal growth factor receptors (EGFR), including EGFR, erbB-2 or HER-
2/neu, erbB-3, and erbB-4, behave like oncogenes in breast cancer due to gene 
amplifications or overexpression, and results in uncontrolled cell proliferation (Bacus 
et al.,1994; Vogelstein and Kinzler, 1998). 
Fibroblast growth factors (FGF) are another group of growth factors involved 
in breast cancer. FGF-3 (mouse int-2), is one of the genes activated by the insertion 
of mouse mammary tumor virus (MMTV), and become oncogenic (Coleman-
Krnacik and Rosen, 1994; DeVita et al., 2001).  
Estrogen and progesterone are important in mammary gland development by 
regulating epithelial growth, differentiation and survival. In addition, these hormones 
are involved in the development of breast cancer. Estrogen receptor (ER) and 
progesterone receptor (PR), through which the hormones act, have an association 
with the prognosis and response to the antihormonal therapy of the patient. Estrogen 
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and progesterone induces the expression of protooncogenes c-MYC, c-FOS, c-JUN. 
In normal tissue, ER and PR are expressed in luminal epithelial cells and dividing 
cells are negative for both receptor. However, most of the breast tumors are steroid 
receptors positive (DeVita et al., 2001; Clarke et al., 2003). 
1.3 Stem Cells and Cancer 
1.3.1 Overview of Stem Cells 
The cells, which have the ability to self-renew and to produce daughter cells 
that will differentiate into different cell types, are called ‘stem cells’. Stem cells are 
classified according to their capacities. The fertilized oocyte and its first daughter 
cells have the capacity to generate whole embryo and the surrounding tissue of 
placenta, and called totipotent stem cells. Throughout the embryonic development 
blastocyst and inner cell mass (ICM) is formed. The ICM cells are pluripotent stem 
cells that can from the all cell types of three germ layers, but not supporting tissue 
and a complete embryo. Adult tissues are thought to have multipotential stem cells 
(Alison et al., 2002). Repair and regeneration are essential in adult tissues, and 
require a stock of cells, the multipotential stem cells, which have an increased 
lifespan, and capacity to generate necessary tissue specific cells. It is easier to detect 
stem cells in tissues with high cell turn over like skin, intestine and bone-marrow. In 
some tissues stem cells are required for regeneration in response to tissue injury like 
in liver, and it is harder to identify these stem cells because they are hidden and 
activated only after an injury or pathologic condition (Nagy, 1995; Presnell et al., 
2002). The last group is unipotential stem cells, which can only generate one type of 
differentiated cell, and sometimes considered as committed progenitor cells, because 
of their limited proliferation and differentiation capacity (Alison et al., 2002). 
The intermediate cells between the stem cells and the terminally 
differentiated cells are called “progenitor cells”, “transit cells” or “transit amplifying 
cells”. A stem cell can generate one stem cell (self-renewal property) and one 
progenitor cell (differentiating daughter cell producing property) by asymmetric 
division, or can generate two identical types of cells by symmetric division. The 
asymmetric division conserves the stem cell compartment, while a symmetric 
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division generating two stem cells cause expansion or symmetric division generating 
two progenitor cells cause depletion of the stem cell compartment (Smalley and 
Ashworth, 2003).  
Stem cells are undifferentiated and usually do not function like their progeny. 
They are thought to be found in very small numbers in the tissues, like 1 in 10,000 in 
haematopoietic tissue, and have a slow rate of proliferation compared to progenitor 
cells (Alison et al., 2002). 
The stem cells are thought to be found in a specific part of the tissue, ‘stem 
cell niche’, which include extracellular matrix (ECM) and supporting cells with 
specific signaling functions. The base of the small intestine is an example for the 
stem cell niche. It was shown that in the case of stem cell depletion, the stem cell 
niche have the capacity to induce the formation of stem cells or can induce the 
progenitor cells to behave like stem cells (Smalley and Ashworth, 2003). 
Stem cells should keep a balance between self-renewal and differentiation. 
Uncontrolled self-renewal will cause problems like tumor formation. It is crucial to 
understand pathways behind the decision of two fates in order to understand the stem 
cell derived tumor formation. The most detailed studies in stem cells are done in 
haematopoietic stem cells (HSC), which are isolated both from mice and human. The 
knowledge about stem cells mostly comes from HSC studies. Activation of notch 
signaling pathway by Jagged-1 ligand promoted HSC self-renewal or maintenance of 
multipotentiality (Varnum-Finney et al., 2000; Karanu F.N., et al., 2000). Sonic 
hedgehog signaling is another pathway that can increase self-renewal capacity of 
human HSC in vitro (Bhardwaj et al., 2001). Overexpression of activated β-catenin, 
which functions at the downstream of Wnt signaling, increased the cell population 
that can reconstitute haematopoietic system in vivo and have stem cell markers in 
isolated HSC. In addition, inhibition of Wnt signaling due to Axin overexpression 
resulted in inhibition of HSC proliferation and reduction in in vivo reconstitution. 
Activation of Wnt signaling results in increased self-renewal and decreased 
differentiation in epidermal (Zhu and Watt, 1999) and intestinal stem cells (Sancho et 
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al., 2003). We may conclude that Wnt signaling plays a role in self-renewal of stem 
cells.  
1.3.2 Stem Cells and Cancer 
Tumors are also tissues that consist of heterogeneous cell populations, they 
can form the required structures like blood vessels to survive, they can metastasize to 
new tissues and form similar tumor tissues, and they can regenerate after surgical 
removal. All these features require a group of cells that have capacity to survive for a 
longer time and differentiate into several distinct cell types. As explained in section 
1.3.1, stem cells have a high capacity to replicate, and live for a longer time 
compared to differentiated cells. These properties give them a greater potential to 
accumulate mutations, which is the main requirement for cancer formation. Trott 
expanded the hypothesis that only a small part, around 1%, of tumor cells behave 
like tumor stem cells, which can proliferate to form both tumor stem cells and 
progenitor cells to differentiate and form heterogeneous cell types of a tumor (Trott, 
1994; Presnell et al., 2002; Smalley and Ashworth, 2003). 
The dedifferentiation of differentiated adult cells was first thought to be the 
origin of cancer, they are thought to gain the ability to proliferate rapidly and give 
rise to different types of cells due to dedifferentiation. However cancer formation 
occurs within several months or years, and requires more than one ‘hit’ that changes 
the cellular behavior. Even when mature cells get the first ‘hit’ they will probably die 
before secondary hits occur. However; stem cells can live long enough to accumulate 
mutations (Sell and Pierce, 1994). Skin is one of the best examples for the stem cell 
origin of cancer. Skin cancer is mostly observed in the middle or late life time; 
however the initial promoting events occur early in life. The mature skin cells have a 
high turn over that, a fully differentiated keratinocyte derived from daughters of stem 
cells, removed from the skin in a day. Since the differentiated skin cells do not have 
enough time to accumulate mutations, there should be long-lived skin stem cells that 
begin to accumulate mutations early at life and give rise to cancer several years later 
(Presnell et al., 2002).  
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Another advantage of stem cells is that they already have self-renewal 
capacity, in contrast to differentiated cells. And uncontrolled activation of self-
renewal will cause tumor formation due to proliferating stem cells. Stem cells require 
fewer mutations to maintain self-renewal capacity compared to differentiated cells, 
which should gain this capacity de novo. So, stem cells are more susceptible for 
being the origin of cancer (Reya et al., 2001). 
Normal stem cells and cancer cells have many similar properties. First of all, 
both have ability to self-renew that stem cells use tightly controlled proliferation 
capacity for organogenesis, adult tissue maintenance, repair, and regeneration; while 
uncontrolled self-renewal of cancer cells cause tumor formation. Second, both can 
differentiate to form different types of tissue specific cells, or organogenesis in the 
case of stem cells and tumor heterogeneity in the case of cancer cells. Third, both 
have active antiapoptotic pathways and telomerase activity, which results in long life 
and high risk of mutation accumulation. Fourth, they have resistance to damaging 
agents. Stem cells have an increased transporter activity to exclude toxic agents, and 
cancer cells can remove chemotherapeutics and become resistant. Last, both can 
survive independent of anchorage and migrate, which gives cancer cells ability to 
metastasize (Dontu et al., 2003a).  
Tu and colleagues hypothesize that heterogeneity of the tumors depends on 
the origin stem cell. If the origin is an early stem cell the tumor will be more 
heterogeneous than the tumors derived from a late stem cell with a narrower 
capacity. The early stem cells will generate tumors containing all cell types of germ 
layers, like in germ cell tumors; intermediate stem cells will generate tumors with 
restricted cell phenotypes, like in respiratory and gastrointestinal cancers; and a late 
stem cell will generate tumors containing only one type of cell, like in basal cell skin 
carcinoma (Tu et al., 2002). 
The signaling of stem cell niche may contribute to tumor formation too. 
Because an abnormality in the signaling can cause accumulation of stem cells and 
that will increase the risk of tumor formation. The repopulation of stem cells by 
progenitor cells in response to stem cell niche signals will also increase the tumor 
formation risk according to the Cairns hypothesis. Cairns hypothesis states that after 
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asymmetric divisions, always stem cells take the original DNA strand, which will 
serve as template for the following divisions. In that case daughter progenitor cells 
always carry the newly synthesized DNA strand, which have more error due to the 
nature of the replication and accumulate mutations (Smalley and Ashworth, 2003).  
Current therapeutic approaches target proliferating cells. However; stem cells 
have a relatively low proliferation rate and will not be affected by traditional 
therapies. Reducing the tumor size will not cure the cancer because it will recur as 
long as the stem cells exist in the tissue. However; a novel therapy targeting the stem 
cells will be effective against the origin of tumorigeneis and prevent recursion. A 
therapy targeting the stem cells may use the advantage of common phenotypic 
properties of stem cells. Instead of designing different therapies for different 
genotypic aberration in each cancer case, removing the stem cells directly may be 
easier. Some cases, like in breast cancer, a preventive treatment can be applied to the 
women in risk group. Since breast is not a vital organ, eliminating cancer prone stem 
cells at early ages will prevent tumor formation. However, these kinds of 
applications should be discussed deeply because depleting whole stem cells may 
generate serious side effects. For example repopulation of stem cells, will result in 
the accumulation of more mutations according to Cairns hypothesis, and this will 
increase the risk of tumorigenesis (Smalley and Ashworth, 2003).  
1.4 Breast Stem Cells  
1.4.1 Breast Stem Cells in General 
Stem cells are mostly studied in detail in blood tissue, because studying with 
blood cells is easier than studying with the solid tissues. As a result, proliferation and 
differentiation process of haematopoietic stem cells are explained in detail, but the 
stem cells of solid tissues are not well identified and studied (Smalley and Ashworth, 
2003). 
The idea of breast stem cells first comes from a study done in 1959, by 
DeOme. He did the first transplantation experiment in breast, and showed that 
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epithelium isolated from different regions of postnatal mammary gland, can generate 
functional mammary epithelial structures.  (Welm et al., 2003) 
 
Figure 1.4 Formation of a duct in developing breast. The inner luminal epithelial 
cell layer and outer myoepithelial cell layer are formed from TEB. Cap cells at the 
tip of the TEB generate two different types of transit cells; first type on the outer site 
differentiate into myoepithelial cells, and second type at the center, called “body 
cells” differentiate into luminal epithelial cells. Central body cells undergo apoptosis 
while outer layer differentiate into the luminal epithelial cells in order to form the 
ductal lumen (Smalley and Ashworth, 2003). 
A stem cell population cannot be identified in breast tissue yet; however it is 
thought that there are cell populations that behave like stem cells in specific 
microenvironments. In developing mammary gland, depending on the structure and 
function of TEB, we can say that the TEB are most probably the structures that 
contain the stem cell activity in breast tissue (Figure 1.4). In terminal end buds, the 
cap cells are the candidates for stem cells because it was shown that they migrated 
into the body cell mass (Smalley and Ashworth, 2003). 
In addition to developing mammary gland, breast stem cells should be found 
in adult mammary gland for at least three processes. During pregnancy, side 
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branches are developed and secretory alveoli are generated to produce milk. Upon 
weaning involution occurs and these structures are removed by apoptosis. In each 
pregnancy this mammary cycle is repeated and dramatic changes occur in breast 
tissue (Figure 1.3). Only stem cells have the capacity to proliferate and differentiate 
into different structures for many times during the life of a female animal. In 
addition, non-pregnant animals have a similar alveolar bud expansion and regression 
process during each menstrual cycle. The other process is the replacement of 
epithelial cells, which are shed into the lumen during cell turnover. The cells may be 
lost during lactation, since they may be found in the milk, or they may be lost in 
resting gland (Smalley and Ashworth, 2003).  
1.4.2 Evidences for Breast Stem Cells 
The experimental techniques like cleared fat pad transplantation, retroviral 
tagging and x-chromosome inactivation patterning gave some evidences about breast 
stem cells. Cleared fat pad transplantation depends on the growth of the epithelia 
after birth, and enables removal of all epithelial cells of host breast and 
transplantation of new epithelial cells. The primary epithelial cells transplanted into 
the cleared fat pads resulted in mostly complete ductal system generation that can 
respond to hormones during pregnancy and generate alveolar cells, less commonly 
only alveoli without ducts, and rarely only ducts without alveoli generation. These 
results show that in the transplanted population there are some cells, which are able 
to form all or a few parts of an adult breast. Retroviral tagging system, in which 
retroviral sequence is incorporated into the host genome and enables marking of the 
cells, and monitoring the progeny of cells transplanted to the cleared fat pads. This 
system showed that entire mammary epithelial growth could be clonal in origin 
(Kordon and Smith, 1998). X chromosome inactivation patterns also showed that 
terminal duct lobular units (TDLU) are clonal, so there may be adult stem cells 
distributed to the mammary gland (Diallo et al., 2001; Welm et al., 2003; Smalley 
and Ashworth, 2003).  
The histological and microscopic studies in mouse and rat identified a cell 
population, which morphologically is a candidate for a stem cell population. The 
small light cells (SLC), are undifferentiated cells in luminal cell layer, near 
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myoepithelial cells, and small in size. SLCs have a pale cytoplasm and do not have 
specialized organelles. They are found together as homogeneous or heterogeneous 
pairs, probably representing symmetric and asymmetric divisions respectively. SLC 
can differentiate into undifferentiated large light cells (ULLC), differentiated large 
light cells (DLLC) and large dark cells (LDC). It is thought that ULLC and DLLC 
are the progenitor/transit cells. Cells similar to SLC are identified in cattle and 
human mammary glands too (Smith and Chepko, 2001). 
Another candidate cell population is identified by bromodeoxyuridine (BrdU) 
labeling experiment, in which the dye is incorporated into DNA and diluted by each 
cell proliferation. Some cells were shown to retain the label for a longer time, and 
that indicates a slow rate of proliferation, which is a property of stem cells. Some of 
these label-retaining cells (LRC) did not express neither luminal nor myoepithelial 
markers, while some express both. So it is thought that undifferentiated LRC stem 
cells can form differentiated transit cells (Welm et al., 2002; Smalley and Ashworth, 
2003). 
As mentioned before, luminal cells are thought to be the candidate for stem 
cell population. Freshly isolated human luminal and myoepithelial cells can be 
grown in specific mediums. When luminal cells are switched to the myoepithelial 
medium, after a certain time some cells with myoepithelial markers, and also some 
other cells with both myoepithelial and luminal markers are observed, indicating the 
intermediate transit cells. However, myoepithelial cells do not give this result 
(Pechoux et al., 1999). In addition, some cells positive for ESA (epithelial specific 
antigen, a marker for luminal cells), negative for MUC1 (luminal epithelial marker) 
and positive for cytokeratin 19, can generate ESA+/MUC1+ cells and myoepithelial 
cells. And when these ESA+/MUC1-/Cytokeratin 19+ cells are grown on three-
dimensional cultures and xenografts, they can form TDLU like structures, and are 
thought to be TDLU progenitors (Gudjonsson et al., 2002; Smalley and Ashworth, 
2003).  
A common property of stem cells is their ability to efflux chemicals like 
chemotherapeutics or Hoechst dye out of their cytoplasm. Side population (SP), is 
accepted as a universal stem cell marker, because it is found in putative stem cells of 
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many tissues. SP cell population also pumps chemicals out of cell. This phenomenon 
is thought to be due to ABC transporter protein ABCG. SP cells are also found in 
breast epithelium of human and mouse, in which they are undifferentiated and 
express none of the cytoskeletal markers of myoepithelial and luminal epithelial 
cells. Depending on the efflux of Hoechst dye SP cells can be isolated from mouse 
mammary gland by FACS. The isolated SP cells were shown to reconstitute 
mammary gland and form ductal and alveolar cell populations. Breast SP cells are 
rich for expression of Sca-1, a stem cell marker. The Sca-1 enriched cells were able 
to reconstitute mammary gland. However since 20-30% of breast cells are positive 
for Sca-1, we can say that this is mixed population containing stem cells. (Welm et 
al., 2003; Smalley and Ashworth, 2003). 
Mammospheres, which is based on the principle that normal epithelial cells 
cannot survive in the absence of a substratum to attach; but in contrast stem cells are 
anchorage independent that they can survive and proliferate in this condition, was 
used to enrich the candidate breast stem cells. Cultured mammospheres lost the 
normal epithelial cells and enriched in the undifferentiated cells. These cells were 
able to differentiate and form myoepithelial, ductal epithelial and alveolar epithelial 
cells. In addition, they had self-renewal capacity that they could form new 
mammospheres containing cells with the same differentiation capacity. These studies 
should be expanded for in vivo experimental conditions as well. The expression 
profiles of mammospheres gave some clues about the pathways important in breast 
stem cells that TGF-β, and growth hormone signaling were activated, and Wnt-1 and 
Notch3 were among the signaling proteins upregulated (Dontu et al., 2003b).    
Depending on these experimental results, we can conclude that there are 
breast stem cells, which are most probably luminal origin, can differentiate into both 
luminal epithelial and myoepithelial cells, and can generate TDLU like structures. 
The probable stem cells are located at the base of luminal epithelial layer, next to 
myoepithelial layer, and do not have a contact with lumen or basement membrane. 
These cells do not express all markers of differentiated luminal epithelial or 
myoepithelial cells, but may express some of them together. They generate transit 
cells, which express markers of both lineage and then differentiate into luminal 
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epithelial or myoepithelial cells. And these cells also express some common markers 
for stem cells (Smalley and Ashworth, 2003).   
In spite of these experimental evidences, we still cannot say that there were 
breast stem cells in adult breast. The self-renewal capacity of the candidate stem cells 
is not shown yet. In order to prove the presence of breast stem cells exactly, the 
breast cells with multipotent differentiation and self-renewal capacity should be 
isolated.  
1.4.3 Breast Cancer Stem Cells 
Breast stem cells are strong candidates for the origin of breast cancer. In 
addition to the general ideas explained in section 1.3.2., some observations also 
supports this idea. For example, women exposed to ionizing irradiation as teenagers 
are more susceptible to breast cancer compared to women exposed as adults. In 40% 
of breast cancer cases, recursion is observed in 10 years after the diagnosis and 
removal of the tumor. So, the origin should have an extremely long life and should 
be found in young women more, with a higher proliferative capacity (Welm, 2003). 
These observations direct us to the breast stem cells as origin of breast caner. 
Al-Hajj et al identified a group of candidate “breast cancer stem cells” in 
human breast tissue. In solid tumors only a small proportion of cells are able to from 
colonies in vitro, and large number of cells are required in transplantation to form 
tumor in animals. So, they think that in a tumor there is small number of cells, which 
have capacity to proliferate and from new tumors. They isolated different group of 
cells depending on the heterogeneous expression of cell surface markers from human 
breast tumors. A specific group of cell, which is positive for cell adhesion molecule 
CD44, negative or has low expression for CD24, and negative for lineage markers 
(CD2, CD3, CD10, CD16, CD18, CD31, CD64, CD140b, which are associated to 
normal cell type and not expressed in cancer cells) was isolated. It is interesting that 
the transplantation of 103 CD44+/CD24-/low/Lineage- cells generated tumor in all 
cases, however transplantation of 104 mixed tumor cells generated tumors in 
minority of cases. In ESA+ subpopulation, even 200 cells give rise to tumor. The 
complexity of the new tumor with respect to ESA, CD24, and CD44 expression 
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patterns is similar to the original tumor, from which CD44+/CD24-/low/Lineage- cells 
were isolated. The newly formed tumor contained tumorigenic CD44+/CD24-
/low/Lineage- cells, representing the self-renewal property. And also the tumor 
contained non-tumorigenic cells with different cell surface marker expression 
patterns, representing the differentiation property. The experiments strongly states 
that CD44+/CD24-/low/Lineage- group of cells have stem cell properties, however in 
order to prove definitely a single cell transplantation should be able to generate 
tumor (Al-Hajj et al., 2003). A possibility is that this group of cells is enriched in 
stem cells, but may also contain non-tumorigenic cells. So, further analysis is 
required for the isolation of exact stem cells within CD44+/CD24-/low/Lineage- group.  
Do the tumor stem cells originated from normal adult stem cells? The 
multipotent cells of breast are also known to express ESA and CD44, which are 
positive in putative tumor stem cells as well (Al-Hajj et al., 2003). In addition, 
depending on the experimental results we can say that they are probably originated 
from normal stem cells. When the epithelial cells of a Wap-TGFβ1 transgenic mouse 
are transplanted to a cleared fat pad, reduced repopulation is observed, and this is 
thought to be due the premature stem cell senescence. And these transplanted 
animals are resistant to MMTV induced tumorigenesis. Another evidence for the 
normal adult stem cell origin of breast cancer stem cells is the protective role of early 
pregnancy against breast cancer. Pregnancy causes terminal differentiation, and 
decreases the proliferative capacity. Early pregnancy results in the increase in 
number of terminally differentiated cells depleting the stem cell compartments before 
they accumulate mutations and begin tumorigenesis (Smalley and Ashworth, 2003). 
1.4.4 Regulation of Breast Stem Cells 
The regulation of stem cell self-renewal and differentiation is based on the 
balance between signaling pathways and many factors like environment. 
Understanding the pathways involved in regulation of self-renewal and 
differentiation will be important to establish the relation between breast stem cells 
and tumorigenesis, and will direct us to novel therapeutic approaches.  
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Wnt signaling is involved in the self-renewal of haematopoietic, epidermal 
and intestinal stem cells as explained in section 1.3.1. Mammosphere experiments 
showed that Wnt pathway components are differentially expressed in putative breast 
stem cells. In addition overexpression of Wnt in the mouse mammary gland by 
MMTV promoter increased tumor formation (Schroeder et al., 2002). So, abnormal 
Wnt signaling may be involved in tumor formation due to stem cell deregulation in 
mammary gland (Dontu et al., 2003a).  
Leukemia Inhibitory Factor (LIF), which stimulates self-renewal of neural 
stem cells and maintenance of embryonic stem cells in undifferentiated state, was 
shown to be involved in mammary gland tumorigenesis. Overexpression of LIF in 
transgenic mouse caused mammary tumor development and its overexpression is 
observed in human breast cancers (Dhingra et al., 1998). PTEN, is another protein 
shown to be involved in self-renewal of neural stem cell self-renewal, and formation 
of neurospeheres, have mutation in breast cancer (Dontu et al., 2003a). 
Notch signaling pathway is an emerging topic in breast stem cells and 
tumorigenesis and will be discussed in the next section. 
1.5 Notch Pathway 
1.5.1 Overview of Notch Pathway 
1.5.1.1 The Structure of Notch Receptors and Ligands 
A Drosophila strain with notches at the end of its wings was first described in 
1917. Later it was identified that this phenotype is related to a partial loss of function 
of Notch gene. Notch gene is evolutionary conserved from flies to mammals (Nam et 
al., 2002; Radtke and Raj, 2003). 
Notch receptor is single-pass transmembrane protein, which is synthesized as 
a single precursor protein but cleaved during transportation to the membrane by a 
furin-like protease in trans-Golgi. This first cleavage of Notch occurs at around 70 
amino acids external to the transmembrane domain and generates two subunits, 
extracellular and transmembrane. The subunits are not dissociated but transported to 
the membrane as a heterodimeric receptor, which is held together by non-covalent 
 24
interactions and calcium. Notch consists of highly conserved structural motifs 
(Figure 1.5). Extracellular subunit of Notch receptor contains 29-36 N-terminal 
epidermal growth factor (EGF)-like repeats, which are involved in ligand binding. 
EGF-like repeats are followed by three tandemly repeated LIN-12 motifs, which are 
required to inhibit activation in the absence of ligand binding. First cleavage site is 
around 100 residues after LIN-12 repeats. The extracellular part of transmembrane 
subunit is very short and consists of conserved cysteine residues. The intracellular 
part of transmembrane subunit contains RAM domain followed by ankyrin/CDC10 
repeats, both of which are involved in binding to the transcription factors in the 
nucleus. Ankyrin/CDC10 repeats are flanked by two nuclear localization signals 
(NLS) and followed by transactivation domain and PEST (PEST for proline, 
glutamate, serine and threonine) sequence (Kadesch, 2000; Nam et al., 2002). 
 
Figure 1.5 Structure of Notch Receptor.  ECN and NTM show the extracellular 
and transmembrane subunits of Notch receptor, respectively. S1, S2 and S3 represent 
the sites of three cleavages in order (Nam et al., 2002).  
Drosophila has only one Notch gene, while C.elegans have two (glp-1 and 
lin-12) and mammals have four (Notch1-4), which are thought to be evolved by gene 
duplication. Mammalian Notch receptors are highly homologues, but have some 
differences in extracellular and cytoplasmic domains (Figure 1.6). Notch1 and 
Notch2 have 36 EGF-like repeats while Notch3 has 34 and the shortest one Notch4 
has 29 repeats. Notch1 has the strongest transactivation domain, Notch2 has a 
weaker one, but Notch3 and Notch4 do not have. Ankyrin/CDC10 repeats are the 
least conserved part of the receptors and affects transactivating activity (Nam et al., 
2002; Radtke and Raj, 2003). 
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Figure 1.6 Human Notch Receptors. Human Notch receptors are highly conserved 
but have differences in the number of extracellular EGF repeats and cytoplasmic 
Ankyrin repeats and transactivating domain (Radtke and Raj, 2003). 
Notch ligands, DSL, are also single-pass transmembrane proteins. Drosophila 
has two ligands Delta and Serrate, while in human, two Serrate homologues Jagged1 
and Jagged2, and three Delta homologues Delta-like1, Delta-like3, and Delta-like4, 
are found. Each of the ligands contain N-terminal DSL motif, which is required for 
receptor interaction. DSL is followed by EGF-like repeats, and then transmembrane 
domain. The cytoplasmic tail of ligands is shorter and consists of 70-215 amino 
acids. The number and spacing of EGF-like repeats are different in ligands. Jagged1 
and Jagged2 have additional cysteine rich domain below EGF-like repeats (Nam et 
al., 2002; Radtke and Raj, 2003). 
1.5.1.2 The Notch Signaling Pathway 
In contrast to usual signaling pathways, Notch signaling does not contain an 
enzymatic amplification step, and Notch receptor itself directly involved in the 
transduction of the signal to the nucleus (Figure 1.7).  
Notch signaling is activated upon interaction with ligand represented by 
adjacent cells. Receptor-ligand interaction disrupts the heterodimeric structure of 
Notch and induces the second proteolytic cleavage. A member of ADAM family of 
proteases, TNF-α converting enzyme (TACE) in human and Kuzbanian in 
Drosophila, cleaves the transmembrane subunit of receptor from a site adjacent to 
membrane. This cleavage induces the third cleavage within transmembrane region,  
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Figure 1.7 Notch Signaling Pathway. S1, S2, and S3 represents the three cleavages 
in order. ICN represents the released intracellular domain of Notch (NICD) (Nam et 
al., 2002). 
which is catalyzed by a complex of Presenilin, nicastrin, Aph1, and Pen2 protein 
complex and releases functional cytoplasmic part, Notch intracellular domain 
(NICD). NICD translocates to the nucleus and interacts with CSL (CSL stands for 
CBF1 in mammals, Su(H) in Drosophila, and Lag-1 in C.Elegans) transcription 
factors. In the absence of Notch signaling CSL binds to the target genes’ promoters 
in a complex with several corepressors and histone deacetylases to inhibit the 
transcription. NICD competes with the inhibitory proteins, like CIR, KyoT2, and 
SMRT. Then displace them and recruit coactivators and histone acetylases like 
CBP/p300, pCAF, GCN5 and Mastemind like protein (MAML) converting CSL 
from repressor to activator, and initiate transcription. The signaling is terminated by 
the rapid degradation of NICD in the nucleus due to ubiquitination by human Sel-10, 
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an E3 ubiquitin ligase (Kadesch, 2000; Nam et al., 2002; Radtke and Raj, 2003; Wu 
and Griffin, 2004). 
The first identified target gene of Notch signaling is HES (Hairy/enhancer of 
split) basic helix-loop-helix transcription factors, which inhibits expression or 
function of Neurogenin, Mash, and MyoD proteins. Notch signaling is thought to 
activate different targets at different tissues. For example in keratinocytes Notch1 
was shown to induce p21Waf1, which has CSL binding site, inhibiting proliferation 
and inducing terminal differentiation (Rangarajan et al., 2001a). CSL binding site is 
also described in cyclin D1 gene, which is upregulated by Notch signaling in rat 
kidney epithelial cells (Ronchini and Capobianco, 2001). Notch1 was shown to 
activate phosphatidylinositol 3-kinase (PI3K), which confers resistance to anoikis 
and p53 mediated apoptosis. ERBB2 and NF-κB2 promoters have CSL binding sites, 
and induced by Notch1 (Chen et al., 1997; Oswald et al., 1998). ERBB2 stimulates 
proliferation, while NF-κB2 is mainly involved in development of lymphoid organs 
and induces expression of many genes, some of which have anti-apoptotic roles 
(Radtke and Raj, 2003; Hansson et al., 2004). 
There are also evidences for CSL-independent signaling of Notch. NICD 
lacking CSL-interacting domain can still function in blocking myogenesis. Deltex 
protein is involved in CSL-independent signaling (Radtke and Raj, 2003; Hansson et 
al., 2004). 
1.5.1.3 Regulation and Crosstalks of Notch Signaling  
Notch receptors are glycosylated by addition of fucose to serine and threonine 
residues of EGF-like repeats by O-fucosyl transferase. The glycsoylation is essential 
for the regulation of Notch activity that loss of function or overexpression of the 
particular enzyme may inhibit Notch activity. Fringe is another enzyme involved in 
modification of O-linked fucose on EGF-like repeats, which are important in ligand 
binding. Modification by Fringe increases the affinity of Notch for Delta while 
decreasing the affinity for Serrate in Drosophila (Schweisguth, 2004). The 
orthologues of Fringe in human are Radical, Manic and Lunatic Fringe, which 
perform gycosylation in Golgi. Similar to Drosophila, modification of Notch inhibits 
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activation by Jagged1 and Jagged2 but not by Delta-like (Dll) ligands in mammals 
(Mumm and Kopan, 2000; Nam et al., 2002). 
The internalization of receptors by endocytosis, and degradation by 
ubiqitination is another mechanism of Notch regulation. Numb is one of the proteins 
that are thought to be involved in endocytosis. The exact mechanism of Numb 
function is not clear but it segregates differentially to daughter cells and affect the 
cell fate by inhibiting Notch (Hansson et al., 2004; Schweisguth, 2004). 
The crosstalk with several pathways may alter the result of Notch signaling 
depending on the cellular context. For example, in C.elegans Ras activation 
downregulates Notch. However, in cultured human cell lines Ras activates Notch 
signaling and Notch is required to maintain Ras induced neoplastic phenotype 
(Weijzen et al., 2002). Wnt signaling has an inhibitory effect on Notch signaling, and 
NICD has a week interaction with LEF-1, and GSK-3β, which is thought to 
phosphorylate and stabilize NICD (Hansson et al., 2004). 
1.5.1.4 Function of Notch Signaling 
Notch is one of the pathways involved in development in coordination with 
the pathways Wnt, Hedgehog, Transforming Growth Factor-β (TGF-β), and 
Receptor Tyrosine Kinase/Phosphatase. Notch signaling is important in several 
cellular processes like maintenance of stem cells, specification of cell fate, 
differentiation, and proliferation depending on the cell type (Mumm and Kopan, 
2000; Radtke and Raj, 2003). 
Maintenance of an undifferentiated state is one of the major roles of the 
signaling. Activated Notch signaling prevents differentiation neuronal progenitor 
cells, while inhibition results in excessive neurogenesis and depletion of progenitor 
cells. In a hematopoietic cell population, induction of Notch signaling by Jagged1, 
increases the stem cell ratio. So, Notch signaling keeps progenitor cells in a stem cell 
like character (Radtke and Raj, 2003). 
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Table 1.1 Knockout Mice of Notch Components 
Gene Knockout Phenotype Reference 
Notch1 Embryonic lethality 
Swiatek et al., 1994; 
Conlon et al., 1995 
Notch2 Embryonic lethality Hamada et al., 1999 
Notch3 No apparent phenotype Krebs et al., 2003 
Notch4 No apparent phenotype Krebs et al., 2000 
Notch1 and Notch4 
More severe phenotype than 
Notch1 null mice 
Krebs et al., 2000 
Notch1 and Notch3 
Embryonic lethality similar to 
Notch1 null mice 
Krebs et al., 2003 
Jagged1 Embryonic lethality Xue et al., 1999 
Delta like1 Embryonic lethality Hrabe et al., 1997 
Delta like3 Skeletal defects 
Kusumi et al., 1998; 
Dunwoodie et al., 2002 
CBF-1 Embryonic lethality Oka et al., 1995 
Notch signaling is also involved in binary cell fate decision, which means the 
determination of a cell fate between two possible options. During development in 
Drosophila, the fate of precursor cells, which can differentiate into neuronal-
precursor or epidermal cells, are determined by Notch signaling. In lateral inhibition, 
Notch receptor and ligands are expressed equally in all cells at the beginning, but the 
concentrations changes over time and cells begin to express either receptors or 
ligands dominantly. The cells expressing ligand differentiate into neuronal cells, 
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while the differentiation in cells with activated Notch signaling is inhibited and they 
adopt epidermal cell fate (Kimble and Simpson, 1997). In inductive cell fate 
determination, two distinct cell types expressing either Notch receptor or ligand 
adopt different cell fates. In bipotential neurol crest stem cells, the Notch expressing 
cells differentiate into glial cells instead of neurons. Notch signaling induces terminal 
differentiation in skin (Radtke and Raj, 2003). 
The knockout mouse models of Notch signaling components established its 
critical role in development that most of the knockouts died (Table 1.1). Depending 
on the double knockout mice, Notch1-/-/Notch4-/-, we can conclude that Notch1 can 
only partially compensate Notch4 functions. However, Notch3 function during 
development can be completely compensated by other Notch receptors that Notch3 
knockout mice have no apparent phenotype, and Notch1-/-/Notch3-/- mice do not have 
more severe phenotype than Notch1-/- mice. 
1.5.1.5 Possible Therapeutic Applications Related to Notch Signaling 
In the cases that Notch is functioning as oncogene, or inducing tumorigeneis 
due to induction of stem-cell self-renewal, inhibition of the pathway may be an 
effective therapeutic strategy. The inhibition may be at different steps of signaling 
like ligand binding, receptor cleavage, or NICD function. Competitive inhibitors 
consist of EGF-like repeats may compete with full-length Notch and interfere with 
ligand binding (Garces et al., 1997). The enzymes involved in second or third 
cleavage of Notch receptor may also inhibit signaling. Truncated Notch, which is 
already activated NICD, is observed in many cancer cases. So, inhibition of NICD 
interaction with CSL may be effective in inhibition. Notch can also function as tumor 
suppressor depending on the tissue. In these cases, activation of the signaling may be 
required by inhibition of NICD degradation in nucleus, activation of CSL 
independently of Notch, or induction of signaling upon increase in ligand may be 
applied (Nam et al., 2002). The multiple function of Notch signaling and enzymes 
involved in Notch cleavage should be considered when designing a therapeutic 
strategy in order to prevent unexpected results.   
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1.5.2 Notch Pathway in Diseases 
CADASIL (cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy) is a hereditary disease, which has features like 
subcortical ischemic strokes and progressive dementia. Most of the CADASIL 
patients have point mutations at the EGF-like repeats of Notch3 extracellular 
domain, and that causes addition or deletion of a cysteine residue (Joutel et al., 
1997). Since disulfide bonds formed between cysteine residues are important in 
protein folding, mutation is thought to affect the folding and cause loss of function 
for Notch3. Extracellular Notch3 accumulation, deficiency in first proteolysis and 
intracellular accumulation of Notch3 is observed in several CADASIL brains and 
cell lines (Nam et al., 2002; Hansson et al., 2004). 
Alagille’s Syndrome is a rare autosomal dominant disease that is caused by 
frameshift mutations in ligand Jagged-1, mainly affecting cysteine residues in EGF-
like repeats. Alagille’s Syndrome caused developmental defects in many organs like 
liver, heart, eye, skeleton, and kidney (Nam et al., 2002). 
Spondylocostal Dysostosis is a malsegmentation syndrome related a Notch 
ligand, Delta-like-3 (Dll-3) mutation. Homozygous mutations in Dll-3 result in 
developmental defects of axial skeleton (Nam et al., 2002). 
1.5.3 Notch Pathway in Cancer 
Notch signaling may induce expression of different proteins, interact with 
other signaling pathways and as a result involved in distinct cellular mechanisms 
including differentiation or proliferation as explained in section 1.5.1. The diversity 
of cellular functions affects Notch activity in cancer that it may act both as a 
tumorsuppressor or oncogene.   
Notch signaling has a potential to function as an oncogene that some of the 
components of siganling were shown to be overexpressed in several cancers like 
renal cell carcinoma, head and neck squamous cell carcinoma, endometrial cancer. 
Another evidence for oncogenic character of Notch signaling is the similarity 
between Epstein-Barr virus, which immortalizes the infected cells. Epstein-Barr virus 
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nuclear antigen 2 functions similar to NICD that it binds to CSL and converts it from 
transcriptional repressor to activator (Brennan and Brown, 2003). In many type of 
cancers Notch play complex roles related to its function in development of the 
particular tissue. 
1.5.3.1 T-cell Leukemia 
Notch was first described as an oncogene in T-cell acute lymphoblastic 
leukemia (T-ALL). It was found that t(7;9)(q34;q34.3) translocation results in the 
breaking of Notch gene, and fusion to the promoter/enhancer region of T-cell 
receptor-β (TCRβ). The breakpoint results in high-level expression of constitutively 
active Notch1, NICD domain (Reynolds et al., 1987; Ellisen et al., 1991). Since all 
T-ALL patients with t(7;9) translocation have the same feature, overexpression of 
active Notch1 is thought to be responsible for T-ALL (Radtke and Raj, 2003). 
Similar to translocation, viral integrations can also generate truncated Notch 
genes. Integration of Moloney murine leukemia virus and feline leukemia virus into 
the Notch1 and Notch2 genes, respectively, cause expression of truncated Notch 
proteins under viral promoters. The abnormal activation of the Notch signaling 
causes T-cell leukemia (Girard et al., 1996; Rohn et al., 1996). 
Mice expressing truncated Notch1 in haematopoietic progenitor cells 
developed T-cell leukemia. B-cell development was inhibited in these mice, and T-
cells were arrested at an immature stage (Radtke, 1999). Notch1 is required for T-cell 
lineage commitment but should be downregulated for complete differentiation of T-
cells. The arrested T-cells with active Notch1 were polyclonal origin and did not 
form tumors for a while, but in time developed monoclonal aggressive tumors. Most 
probably Notch1 activation arrests cells before terminal differentiation and allow 
their survival and additional mutations achieve transformation in T-cell leukemia 
(Radtke and Raj, 2003; Zweidler-McKay and Pear, 2004). 
Hes1 was shown to be important in T-cell development as a target of Notch 
signaling. However, overexpression of Hes1 did not induce T-cell tumors indictaing 
that other target genes of Notch should be involved in T-cell leukemia. Deltex1 is 
one of the candidates that inhibit T-cell differentiation when overexpressed, but loss 
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of function studies are required to determine its exact role. NF-κB may play a role in 
Notch induced T-cell leukemia. Notch can inhibit NF-κB activity by acting like IκB. 
In addition, active Notch3 may cause constitutive activation of NF-κB (Zweidler-
McKay and Pear, 2004).  
1.5.3.2 Neuroblastoma 
Neural stem cells give rise to neuron and glial cells and Notch is important in 
cell fate decision during this process. Notch signaling mainly blocks differentiation, 
keeps cell at undifferentiated state, and also may induce glial cell fate. Notch 
signaling was shown to be active in neuroblastoma cell lines and Notch3 is expressed 
almost 50% of neuroblastoma cell lines. The experimental results support the idea 
that Notch signaling function to keeping cells in a more stem cell like phenotype, but 
further evidences like neuroblastoma formation upon Notch activation is needed 
(Pahlman et al., 2004). 
1.5.3.3 Skin Cancer 
Notch signaling induces differentiation and keratinocyte stem cells 
commitment to transient amplifying cell populations. Activation of Notch signaling 
in mouse keratinocytes cause cell cycle arrest by p21 expression, and induce terminal 
differentiation (Lefort and Dotto, 2004).  
Mice with deficient Notch1 in epithelia develop basal-cell carcinoma like 
tumors, become more susceptible to chemical-induced carcinogenesis in skin 
(Nicolas et al., 2003). As a result we can conclude that Notch function as a tumor 
suppressor skin, that its absence may not be the direct cause of cancer but mediates 
the accumulation of mutations due to increased proliferation of cells.  
1.5.3.4 Lung Cancer 
During lung development Notch1 is involved in airway epithelial 
development by inducing expression of HES1. Aberrant lung morphology in mice 
with Hes-1 mutation and expression of Notch receptors and ligands, Dll1 and 
Jagged1, suggests that Notch signaling plays a role in normal lung development. 
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Notch signaling is thought to down-regulate epithelial differentiation in lung (Collins 
et al., 2004).  
Notch may function both as an oncogene or tumorsuppressor depending on 
the type of lung cancer. Non-small cell lung cancer (NSCLC) cell lines express 
significant levels of Hes-1 while small cell lung cancer (SCLC) cell lines express at 
low or undetectable levels. Notch1, Notch2 and Notch3 are frequently expressed in 
NSCLC tumors but not in SCLC. Notch signaling seems to play a growth promoting 
role in NSCLC; however overexpression of activated Notch1 and Notch2 inhibits 
growth of SCLC cells representing a tumorsuppressor function (Collins et al., 2004). 
1.5.3.5 Cervical Cancer 
Oncoproteins E6 and E7 of HPV, which is responsible for almost 99% of 
cervical cancers, require active Notch to be able to fully transform human 
keratinocyte cell line HaCaT (Rangarajan et al., 2001b). In early stage cervical 
cancer tumors, cytoplasmic and nuclear staining of Notch1 and Notch2 was detected 
(Zagouras et al., 1995). These results indicate that Notch contributes to initiation of 
cervical tumors together with HPV. However, invasive cervical tumors and 
malignant HPV-positive cervical cancer cell lines had a lower Notch1 expression, 
indicating a reduction in Notch1 level by the progression of cancer. Notch1 
expression reduced E6 and E7 expression (Talora et al., 2002). Notch1 activity may 
be required for the initiation of cervical cancer but disappear for progression.   
1.5.4 Notch Pathway in Breast Development and Breast Cancer 
The first evidence about the contribution of Notch signaling to mammary 
gland tumorigenesis is the identification of MMTV integration sites in Czech II mice 
(Gallahan et al., 1987). In 20% of tumors developed in those mice, MMTV was 
shown to be integrated into the int-3 locus, Notch4 gene. Notch1 was later 
characterized as an integration site for MMTV (Dievart et al., 1999). In both cases, 
MMTV integrates within the Notch genes and results in the expression of truncated 
Notch protein, which is the active form of receptor. These first studies suggested that 
aberrant activation of Notch signaling may contribute to mammary gland 
tumorigenesis (Callahan and Raafat, 2001; Politi et al., 2004). 
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MMTV integration disrupts several genes like Wnt-1, Wnt-3, Wnt-10B, 
FGF3, and FGF4; and generates mammary tumors. The long terminal repeat (LTR) 
of MMTV fuses to the affected gene and act as a promoter/enhancer to initiate 
transcription of altered gene. The expressed truncated Notch proteins have a gain 
function mutation and are constitutively active (Politi et al., 2004). 
Several studies used MMTV integration in order to characterize the role of 
Notch4 in mammary gland development and tumorigenesis. Overexpression of 
truncated Notch4 in transgenic mice resulted in incomplete differentiation of 
mammary epithelium and induced proliferation of immature ductal cells (Smith et 
al., 1995). Another study used mice with MMTV integrated Notch4 gene, and 
showed that in TEB of virgin animals cannot be detected and lower level of 
branching is observed. During pregnancy, ductal epithelium expanded through fat 
pad due to hormonel stimulation, but no alveoli development and expression of milk 
proteins occurred. Within 4-6 months all of the mice developed poorly differentiated 
mammary adenocarcionomas (Jhappan et al., 1992). Truncated Notch4 expression is 
activated by WAP (whey acidic protein) promoter in order to activate Notch4 
signaling only in secretory mammary epithelia of pregnant mice. The ductal growth 
was normal in virgin mice, but secretory lobule growth and differentiation was 
inhibited. Mammary tumors similar to the tumors formed in MMTV activated 
Notch4 mice, occurred within 6 months (Gallahan et al., 1996). The experimental 
results of transgenic mice studies state that Notch4 signaling has an inhibitory role in 
differentiation of ductal and alveolar epithelium in mammary gland.  
TAC2 is cultured mammary epithelial system, which can form branching 
morphology in vitro in response to FGF. The TAC2 cells with activated Notch4 
supported the transgenic experiments that differentiation and branching was inhibited 
(Uyttendaele et al., 1998; Soriano et al., 2000).    
Truncated Notch4 expression is detected by Northern blott analysis in some 
of the breast cancer cell lines (BT474, MDA MB 231, MDA MB 468, SK BR3, 
T47D, ZR-75-1). This truncated form was able to transform normal human 
mammary epithelial cell line MCF-10A, which gain the capacity to grow on soft agar 
(Imatani and Callahan, 2000).    
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The experimental evidences states that Notch4 activity is involved in 
mammary epithelial differentiation in ductal branching, lobuloalveolar differentiation 
and lactation. Notch4 staining detected expression at the proliferating TEBs in 
mammary gland, which are the structures containing putative stem cells (Smith et al., 
1995). Notch4 activation also induced tumor formation in mice models. As a result 
we can conclude that the activated Notch4 signaling keeps mammary epithelial cells 
in an undifferentiated, proliferative state, in a stem-cell like phenotype and that 
makes cells more susceptible to accumulation of additional mutations increasing 
cancer risk. 
Introducing Notch1 NICD encoding cDNA to HC11 mouse mammary 
epithelial cells transform the cells and they became able to form colonies on soft 
agar. This effect requires CSL binding region and NLS of Notch1, and was specific 
to mammary epithelial cell line that rat fibroblasts did not gain the same property by 
Notch1 NICD expression. However the transplantation of HC11 cells expressing 
activated Notch1, did not generate tumors in mice (Dievart et al., 1999). These 
results support the idea that Notch activation can generate the necessary conditions 
like undifferentiated and proliferative phenotype, and additional mutations are 
required for tumor formation (Politi et al., 2004).  
Notch1 signaling was shown to be positively affected by Ras signaling that 
Ras positive breast tumors had an increased Notch1 expression. In cell culture, 
inhibition of Ras signaling blocked upregulated Notch1 NICD, and overexpression of 
Ras increased Dll1 ad Presenilin1 expression, which may activate Notch signaling 
(Weijzen et al., 2002). The Ras-Notch interaction may play a role in mammary gland 
tumorigensis.  
Notch1 and Notch4 expression was detected in human breast tumors. Both 
receptors were negative in normal breast tissue while Notch1 was positive in 67% 
and Notch4 was positive for 44% of DCIS samples (Siziopikou et al., 2002).    
Musashi-1 is an RNA binding protein, and identified as a stem cell marker in 
neuronal stem cells. Msi-1, the human homologue of Drosophila Musashi-1 protein 
is involved in Delta/Notch pathway during asymmetric cell division. Msi-1 interacts 
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with Numb RNA and induces its degradation. Msi-1 was shown to be enriched in 
human breast LRC, which are putative breast stem cells. Inhibition of Msi-1 
translation releases the repression on Delta/Notch signaling in asymmetric cell 
division. When Msi-1 is found in the cells Notch1 was found to be released from 
membrane and activated. It is suggested that in a breast stem cell division, the 
daughter cell expressing the Msi-1 will have the active Notch-1 and replace the stem 
cell, while the Msi-1 negative daughter cell will be committed to differentiation. 
Aberrant Notch signaling may cause symmetric division instead of asymmetric 
division (Clarke et al., 2003). 
Mainly Notch1 and Notch4 are studied in breast cancer. Notch3 was found to 
be upregulated in mammospheres, which is enriched in breast stem cells (Dontu et 
al., 2003b). So, Notch3 may play a critical role in breast tumorigenesis originated 
from breast stem cells. Other components of the Notch pathway should be 
investigated further for their possible roles in breast cancer.     
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CHAPTER 2      AIM OF THE STUDY 
2.1 Aim 
Recent evidences hypothesize that there are cancer stem cells in the origin of 
cancer. In contrast to classical hypothesis, it is being clarified that not all of the cells 
in a tumor have capacity to proliferate, but cancer stem cells with deregulated 
proliferation and differentiation properties are forming tumors. The adult stem cells 
are trying to be isolated in breast tissue. A candidate population of breast cancer stem 
cells, which are thought to be originated from adult breast stem cell, have recently 
been isolated. Investigation of pathways behind the tumor formation of cancer stem 
cells is the initial step in the generation of novel therapeutic approaches against 
cancer. Notch signaling is one of the pathways involved in stem cell maintenance, 
and its activity in some of the human tumors was established. Activation of Notch 
signaling in mouse mammary tumors due to MMTV integration, and its role in 
mammary gland development lead us to the possible role of Notch signaling in 
human breast cancer. There is no complete data about any expression alteration of 
Notch receptors and ligands in human breast cancer.  
This study tries to answer the question if Notch signaling has a role in human 
breast cancer, and if so, how it contributes to tumorigenesis? The specific aim is to 
investigate the expression status of all Notch receptors and ligands in human breast 
cancer cell lines and breast tumors in order to identify any abnormality that may 
direct us to the significance of Notch signaling in breast cancer.     
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2.2 Strategy 
Six breast cancer cell lines (T47D, BT 474, MCF-7, BT 20, MDA MB 468, 
MDA MB 453), and eight breast tumor samples were used to study expression of 
four Notch receptors (Notch1, Notch2, Notch3, and Notch4) and five ligands 
(Jagged1, Jagged2, Delta-like protein1, Delta-like protein3, and Delta-like protein4). 
A normal mammary epithelial cell line, hTERT-HME1, immortalized with hTERT 
expression was used as normal control for both cell lines and tumor samples. The 
expression was detected by semi-quantitative RT-PCR. 
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CHAPTER 3      MATERIALS AND METHODS 
3.1 Tissue Culture 
Six breast cancer cell lines, listed in Table 3.1, were grown as monolayer in 
150 mm culture dishes. Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 
and 0.1 mM non-essential amino acids, is used as medium.  
Table 3.1 Human Breast Cancer Cell Lines Used in This Study 
Cell Lines Cancer Type 
T-47D Metastasis to pleural effusion ductal carcinoma  
BT 474 Breast ductal carcinoma 
MCF 7 Metastasis to pleural effusion adenocarcinoma 
BT 20 Breast carcinoma 
MDA MB 468 Breast adenocarcinoma 
MDA MB 453 Metastasis to pericardial effusion metastatic carcinoma 
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hTERT-HME1 (Clontech), a normal mammary epithelial cell line 
immortalized with hTERT expression, was used as normal control for both cancer 
cell lines and breast tumors. hTERT-HME1 was grown in a specific medium 
prepared with equal amounts of HAM’S F-12 Medium and DMEM supplemented 
with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, 0.1 
mM non-essential amino acids, 10 mM HEPES Buffer, 3.5 ng/ml insuline, 0.1 mg/ml 
EGF, and 0.5 µg/ml hydrocortisone.  
All cell lines were kept in an incubator at 37oC and 5% CO2, and all 
applications were performed under sterile hoods in cell culture facility. All mediums 
and solutions were warmed at 37oC, and wiped with 70% alcohol before placing 
under the hood. For all washing steps PBS, prepared as below, was used. 
Phosphate Buffered Saline (PBS): 
10 X Stock solution (1 lt): 80g NaCl 
    2 g KCl 
    7.64 g Na2HPO4.2H2O  
    2 g KH2PO4 
1 X working solution: 10 X stock solution is diluted to 1 X with ddH2O and pH is 
adjusted to 7.4. Solution is autoclaved and kept at 4oC.  
3.1.1 Thawing of Cells 
The vial of the frozen cell line was taken from liquid nitrogen tank and 
immediately immersed in 37oC water bath and frozen cell suspension was thawed. 
Then cells were transferred to 15 ml falcon tubes containing 10 ml fresh DMEM or 
specific medium of hTERT-HME1, and centrifuged at 1500 rpm for 5 minutes at 
4oC. The supernatant was discarded and cell pellet was resuspended in 10 ml fresh 
medium. Cells were plated into 75 mm culture flasks including 10 ml medium. The 
cells were left in the incubator overnight and medium was refreshed on the following 
day.   
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3.1.2 Subculturing of Cells 
The medium of cells were refreshed every two or three days. Cells were 
splitted when they reached 80-90% confluency. The medium was aspirated and cells 
were washed two or three times with PBS (pH 7.4). Then enough trypsin/EDTA 
solution to cover plate surface is added. Cells were incubated in the incubator till 
they detach from the plate (1 to 5 minutes depending on the cell line). Trypsin was 
immediately inactivated by addition of some fresh medium. Then cells are plated in 
new 150 mm culture dishes at the desired dilution.    
3.1.3 Freezing of Cells 
The cells were grown in 150 mm culture dishes in order to obtain 70-80% 
confluency at the end of two or three days. The medium was aspirated and cells were 
washed with PBS two or three times. Enough amount of trypsin/EDTA solution was 
added and cells were incubated in the incubator till detachment. 10 ml fresh medium 
was added onto the detached cells immediately and cells were centrifuged at 1500 
rpm for 5 minutes at 4oC. Supernatant were aspirated and cells were resuspended in 1 
ml ice-cold freezing medium consists of 10% DMSO, 20% FCS, and 70% medium 
(DMEM or specific medium of hTERT-HME1). Cells were transferred to cryotubes, 
first kept at -20oC till the solution freeze (not more than two or three hours), then put 
into -80oC overnight, and placed into the liquid nitrogen tank on the following day.  
3.1.4 Preparation of Cell Pellets for RNA Isolation 
The cells were grown in 150 mm culture dishes in order to obtain 70-80% 
confluency at the end of two or three days. The medium was aspirated and cells were 
washed with PBS four or five times. Enough amount of trypsin/EDTA solution was 
added and cells were incubated in the incubator till detachment. Cells were collected 
into a 15 ml tube with 10 ml ice-cold PBS, and centrifuged at 1500 rpm for 5 
minutes at 4oC. Supernatant was aspirated. Cell pellet was resuspended in 1 ml ice-
cold PBS, transferred to a 1.5 ml eppendorf tube, and centrifuged at 13000rpm for 3 
minutes at 4oC. Supernatant was aspirated. Cell pellet was directly immersed in 
liquid nitrogen and then kept at -80oC till RNA isolation.  
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3.1.5 Tumor Samples 
Eight human breast tumor samples were obtained from Dr. Betül Bozkurt 
from Ankara Numune Eğitim ve Araştırma Hospital. The available data about the 
patients are listed in Table 3.2. 
Table 3.2 Human Breast Tumor Samples Used in This Study 
Tumor Age Type ERBB status 
T-29 58 IDC Positive 
T-43 43 IDC Positive 
T-44 50 IDC Positive 
T-47 37 IDC Positive 
T-57 51 mucinous (colloid) 
carcinoma Negative 
T-58 62 IDC Not Known 
T-59 34 Mixed IDC and 
ILC Positive 
T-94 37 IDC Negative 
 
3.2 RNA Isolation and Quantification 
RNA isolation from cell pellets and frozen tissues was performed with 
NucleoSpin RNA II Kit (Macherey-Nagel) according to the instructor’s manual. At 
the last step, resuspension of RNA was done with 40 or 50 µl of Rnase free water 
supplied by the kit. Isolated RNA was immediately immersed in liquid nitrogen and 
the stored at -80oC. For the spectrophotometric measurement of RNA concentration 
4 µl sample was diluted in 400 µl 0.1% DEPC treated ddH2O, and measured with 
BECKMAN DU 640.   
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3.3 cDNA Synthesis 
4 µg RNA was used for cDNA synthesis in 30 µl reaction volume. cDNA 
synthesis was done with RevertAid First Strand cDNA Sybthesis Kit (Fermentas) 
according to the instructor’s manual. cDNAs were stored at -20oC.   
3.4 Semi-Quantitative RT-PCR 
3.4.1 Reaction Conditions and Primers  
Semi-quantitative RT-PCR is used to compare gene expression levels of 
samples with each other at RNA level. GAPDH, which is a housekeeping gene, was 
used as equal loading control. GAPDH expression levels should be equal in cDNAs 
synthesized from equal amount of RNA. The cycle number of RT-PCR reactions 
should be optimized to detect expression levels before saturation of amplification. 
The optimized cycle number is 24 for GAPDH and 35 for other genes. PCR reactions 
were performed in the conditions below: 
94oC 5 minutes 
 94oC 30 seconds 
 Tm 30 seconds      Optimized number of cycles 
 72oC 30 seconds 
72oC 10 minutes 
Forward and Reverse primers were designed from different exons for each 
gene by using primer3 program. The sequence of primers, annealing temperatures 
(Tm) and product sizes are listed in Table 3.3.  
Negative control in each RT-PCR reaction contains all components but not 
cDNA. Instead of cDNA, equal amount of sterile PCR water was used. 
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Table 3.3 Sequences of Primers, Annealing Temperatures and Product Sizes 
Gene Sequence (5’ to 3’) Tm Product Size (bp) 
Forward cgc ctt tgt gct tct gtt ctt 
Notch1 
Reverse cat tct ggt tgt cgt cca tga 
61oC 209 
Forward ttg aca acc gcc agt gtg tt 
Notch2 
Reverse tga caa cag caa cag caa gga 
63 oC 183 
Forward att gcc gtc agt gga ctc aa 
Notch3 
Reverse gat cag gtc gga gat gat gct a 
61 oC 239 
Forward ggc tga aga aaa gct agg agg a 
Notch4 
Reverse gga caa atc cac acc cat ga 
63 oC 133 
Forward gcc gtt gca gaa gta aga gtt c 
Jagged1 
Reverse caa cag atc caa gcc aca gtt a 
60 oC 101 
Forward gtc aag gtg gag acg gtt gt 
Jagged2 
Reverse ctc ctc tcc cgc tct ttc ct 
60 oC 146 
Forward ggg tgg aga agc atc tga aa 
Dll1 
Reverse agt ctt gcc atc tca ctt cca 
59 oC 116 
Forward aac aac cta agg acg cag ga 
Dll3 
Reverse gcg tag atg gaa gga gca gat a 
59 oC 119 
Forward aca gca aaa cca cac att gg 
Dll4 
Reverse atc cga cac tct ggc ttt tc 
59 oC 144 
Forward ggc tga gaa cgg gaa gct tgt cat 
GAPDH 
Reverse cag cct tct cca tgg tgg tga aga 
62 oC 143 
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3.4.2 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to analyze RT-PCR results. 2% (w/v) 
agarose gel was prepared with 1X TAE Buffer, and 30 ng/ml ethidium bromide 
solution was added for visualization. Samples were prepared by addition of 5 µl 6 X 
loading buffer to each 25 µl product, and 20 µl was loaded to each well. 5 µl of 
GeneRuler 100 bp DNA Ladder (Fermentas) was used as DNA size marker. Agarose 
gel was run at 80V for 40 minutes and visualized under BioRad Transilluminator. 
MultiAnalyst software was used to take photographs of the gels.    
Tris Acetic Acid-EDTA (TAE) Buffer: 
50 X Stock solution (1 lt): 242 g Tris Base 
   57.1 ml Glacial Acetic Acid 
   37.2 g Na2EDTA.2H2O 
1 X working solution: 50 X stock solution is diluted to 1 X with dH2O. 
6 X Gel Loading Buffer (10 ml): 0.020 g Bromophenol Blue 
     0.020 g Xylene cyanol 
     6 ml Glycerol 
     1 mM EDTA 
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CHAPTER 4      RESULTS 
4.1 Expression of Notch Receptors and Ligands in Human Breast 
Cancer Cell Lines Detected by Semi-Quantitative RT-PCR 
Expression of Notch receptors and ligands were detected in six breast cancer 
cell lines (T47D, BT 474, MCF-7, BT 20, MDA MB 468, MDA MB 453) and one 
normal mammary epithelial cell line, hTERT-HME1. hTERT-HME1, which is 
immortalized with hTERT expression, was used as a normal control. GAPDH was 
used as an equal loading control.  
The expressions of three Notch receptors were detected by semi-quantitative 
RT-PCR (Figure 4.1). Notch4 RT-PCR did not give positive results in any of the cell 
lines. Notch1 is weekly expressed in hTERT-HME1, while Notch2 has a relatively 
strong signal, and Notch3 is not expressed. Notch1 is expressed strongly by six 
breast cancer cell lines, so we can say that Notch1 expression is increased in cancer 
cell lines compared to hTERT-HME1. Notch2 is expressed almost equally in cancer 
cell lines and no change is observed compared to hTERT-HME1. The faint band at 
around 371 bp in Notch2 occurs due to genomic DNA contamination of RNA. 
Primers also amplified the genomic DNA including 188 bp intronic sequence. 
Notch3 has the strongest signal among receptors. All six breast cancer cell lines 
express Notch3 extensively. So, we can say that Notch3 is upregulated in breast 
cancer cell lines.   
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Figure 4.1 Expression of Notch receptors in breast cancer cell lines detected by 
semi-quantitative RT-PCR. First lane shows the marker and last lane shows the 
negative control. The sizes of amplified fragment for Notch1, Notch2 and Notch3 are 
209, 183, and 239 respectively. The upper band around 371, in Notch2 figure is the 
genomic DNA amplification product. GAPDH is used as equal loading control. The 
red arrow head shows the 200 bp size marker.    
Figure 4.2 represents the expression of four Notch ligands detected by semi-
quantitative RT-PCR. Similar to Notch4, Dll4 RT-PCR gave negative results for all 
cell lines too. In contrast to receptors, hTERT-HME1 expresses all of the ligands at 
high levels. Jagged1 is expressed in all of the cell lines, so there is no change 
compared to hTERT-HME1. Jagged2 is negative only in one cancer cell line, MCF7, 
and no change is observed for others. Dll1 is also negative only in one cancer cell 
line, MDA MB 468, and not changed in others. Dll1 has a genomic DNA 
contamination at around 241, which is the size of expected fragment including 125 
bp intronic sequence.  Dll3 is expressed weaker in two of the cell lines, MCF-7 and 
BT 474, and it is negative in two of the cancer cell lines, T47D and MDA MB 453.  
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Figure 4.2 Expression of Notch ligands in breast cancer cell lines detected by 
semi-quantitative RT-PCR. First lane shows the marker and last lane shows the 
negative control. The sizes of amplified fragment for Jagged1, Jagged2, Dll1 and 
Dll3 are 101, 146, 116, and 119, respectively. The upper band around 241 in Dll1 
figure is the genomic DNA amplification product. GAPDH is used as equal loading 
control. The red arrow head shows the 200 bp size marker.       
4.2 Expression of Notch Receptors and Ligands in Human Breast 
Cancer Tumor Samples Detected by Semi-Quantitative RT-
PCR 
Eight different human breast tumor samples are used in semi-quantitative RT-
PCR experiments. The results are compared with hTERT-HME1 as a normal control. 
GAPDH is used for equal loading control.  
Figure 4.3 represents the expression of three Notch receptor expression in 
breast tumor samples. Notch1 has a weak expression generally. Notch1 levels in six 
of the tumors are almost equal to hTERT-HME1, while two of them, T-57 and T-59, 
have a lower expression. Notch2 is negative only in one of the tumors, T-43, and has 
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significant increase in four of them, T-29, T-47, T-57 and T-58, compared to 
hTERT-HME1. A genomic DNA amplification is seen at around 371, similar to the 
Notch2 results in cell lines. Notch3 has the most interesting result that six of eight 
tumors (75%) have significantly upregulated compared to hTERT-HME1.  
 
Figure 4.3 Expression of Notch receptors in human breast tumor samples 
detected by semi-quantitative RT-PCR. First lane shows the marker and last lane 
shows the negative control. ‘T’ indicates the ‘Tumor’. The sizes of amplified 
fragment for Notch1, Notch2, and Notch3 are 209, 183, and 239, respectively. The 
upper band around 371, in Notch2 figure is the genomic DNA amplification product. 
GAPDH is used as equal loading control. The red arrow head shows the 200 bp size 
marker.  
Figure 4.4 represents the expression of four Notch ligands in eight breast 
tumor samples. Jagged1 is expressed in all of the tumor samples almost at equal 
levels in four of the tumors and a slight decrease is observed in other four samples, 
T-29, T57, T-58 and T-94 with hTERT-HME1. Jagged2 is negative only in T-58, has 
a lower expression in T-43, T-44 and T-47, and equally expressed in four other 
tumor samples. Only two of the eight tumors, T29 and T-43, express Dll1, and 
expression is quite weak. Dll3 is expressed by all tumor samples except T-44, the 
expression level is slightly lower than hTERT-HME1 in five of the tumors, T-29, T-
43, T-47, T-58, T-94.  
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Figure 4.4 Expression of Notch ligands in human breast tumor samples detected 
by semi-quantitative RT-PCR. First lane shows the marker and last lane shows the 
negative control. ‘T’ indicates the ‘Tumor’. The sizes of amplified fragment for 
Jagged1, Jagged2, Dll1 and Dll3 are 101, 146, 116, and 119, respectively. GAPDH is 
used as equal loading control. The red arrow head shows the 200 bp size marker. 
4.3 Summary of Results 
Table 4.1 summarizes the expression results of Notch receptors and ligands in 
breast cancer cell lines and human breast tumors. Notch1 is increased in cell lines, 
but not in tumors, while Notch2 is increased in half of the tumors but no change is 
observed in cell lines. However Notch3 is significantly upregulated in both cancer 
cell lines and tumors. Ligands are positive in hTERT-HME1, but no increase is 
observed in cell lines or tumors. The expression of ligands generally do not change 
or negative in cell lines, and decreased or negative in tumor samples.  
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Table 4.1 Summary of Expression Results. 
Gene Family Genes HTERT-HME1 Breast Cancer Cell Lines 
Human Breast 
Tumors 
Notch1 Weakly Positive Increased (6/6) 
Decreased (2/8) 
No change (6/8) 
Notch2 Positive No change (6/6) 
Increase (4/8) 
No change (4/8) 
Notch3 Negative Increased (6/6) Increased (6/8) 
Receptors 
Notch4 Not Detected Not Detected Not Tested 
Jagged1 Positive No change (6/6) 
Decrease (4/8) 
No change (4/8) 
Jagged2 Positive 
No change (5/6) 
Negative (1/6) 
Decreased (3/8) 
Negative (1/8) 
Dll1 Positive 
No change (5/6) 
Negative (1/6) 
No change (2/8) 
Negative (6/8) 
Dll3 Positive 
Decrease (2/6) 
Negative (2/6) 
Decrease (5/8) 
Negative (1/8) 
Ligands 
Dll4 Not Detected Not Detected Not Tested 
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CHAPTER 5      DISCUSSION AND FUTURE 
PERSPECTIVES 
Expression of Notch receptors and ligands in human breast cancer cell lines 
and breast tumor samples was detected by semi-quantitative RT-PCR to investigate 
any alterations compared to normal cell line, hTERT-HME1. 
hTERT-HME1 was immortalized by stable expression of human telomerase 
reverse transcriptase (hTERT) in primary human epithelial cells. It has the 
indefinitely division capacity of transformed cell lines but normal in function and 
phenotype. Transformation requires coexpression of hTERT and other oncogenes. 
Five pathways, including pRb, p53, Ras, hTERT and PP2A should be disrupted in 
order to obtain a transformed cell line. hTERT-HME1 has only hTERT expression 
and has normal p53 expression. hTERT-HME1 has an extended life span but in 
contrast to transformed cell lines it is anchorage dependent, genetically stable, has a 
normal diploid karyotype, does not grow in soft agar and form tumor in nude mice 
(ClONTECHniques, 2000; http://web.mit.edu). Using hTERT-HME1 has many 
advantages over using normal tissues as control. For example, it is easy to grow cell 
line and obtain enough material for RNA or protein isolation. It is usually harder to 
obtain enough normal tissue and isolate qualified RNA. Normal breast tissue also 
contains fat, and epithelial part may not be separated effectively. However; 
immortalized cell line has some limitations too. hTERT-HME1 results cannot be as 
informative as normal tissue because comparison of tumors with their normal pairs 
 54
directly shows the altered expression patterns specific to tumor cells. In addition, 
ectopic hTERT expression may cause some alterations in the cell. For example, in a 
study, decrease in p16 expression was observed in late passages of immortalized 
human mammary epithelial cell line (Kim et al., 2002). Indeed p16 expression is 
negative in hTERT-HME1. In this study, we planned to use normal breast tissues of 
each tumor sample for normal-tumor comparison. However, RNA and cDNA quality 
of normal samples were not good enough, GAPDH RT-PCR results was not equal to 
tumors and there were not enough cDNA. So, hTERT-HME1 was used as normal 
control for both cell lines and tumor samples.   
Expression of Notch receptors and ligands in hTERT-HME1 can represent 
expression patterns of normal mammary epithelial cells generally as explained 
above. Notch1 is weekly expressed, while Notch2 expression is significantly positive 
and Notch3 expression is negative. Expression of all ligands are positive, especially 
Jagged1 has strong expression in hTERT-HME1.     
Notch1 expression increased in cancer cell lines compared to hTERT-HME1, 
but no change is observed in tumor samples that they express Notch1 as weak as 
hTERT-HME1. The increase in cancer cell lines was expected because of the 
previous data. Notch1 was one of the MMTV disrupted gene, and overexpression 
causes mammary gland tumorigenesis in mice (Dievart et al., 1999). In another 
study, Notch1 overexpression is detected in DCIS samples (Siziopikou et al., 2002). 
In this study, in vivo results are not consistent with the increase in cell lines. 
However, Notch1 is still positive in all tumor samples, and comparison of tumors 
with immortalized cell line may be the reason of the inconsistency with the 
overexpression in the previous studies. The expression status of Notch1 in normal 
breast tissue should be identified to further analyze this data.  
Notch2 expression does not change in cell lines, but an increase is observed 
in 50% (4/8) of the tumor samples. Notch2 was not extensively studied in breast, but 
it is known to be involved in other cancer types. Activation due to viral integration 
causes T-cell leukemia in cats, and expression in NSCLC and early cervical tumors 
was detected (Rohn et al., 1996, Collins et al., 2004; Zagouras et al., 1995). 
However, we cannot be sure if the increase detected in this study is significant 
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because it is not supported by cell lines. The number of tumor samples should be 
increased and expression of Notch2 should be identified in normal breast tissue too.   
Exposure of receptors to ligands is another way to activate Notch signaling. 
So, the expression of Notch ligands, Jagged1, Jagged2, Dll1, and Dll3 are also 
checked by RT-PCR. In contrast to receptors, all ligands are strongly expressed in 
hTERT-HME1.  
Jagged1 expression has no change in all cell lines, and only a slight decrease 
is observed in 50% (4/8) of tumor samples. Jagged1 mutations were identified in 
Alagille’s syndrome, so it is important in development (Nam et al., 2002). However, 
an abnormality in Jagged1 expression was not reported in cancer. As a result, we can 
conclude that Jagged1 is expressed by all of the cell lines and tumor samples, so it 
may have a role in the activation of Notch signaling.  
Jagged2 is almost equally expressed in all cell lines, and negative only in one 
of them. One of the tumor samples does not express Jagged2, and 37.5% (3/8) has 
decreased expression. We cannot conclude that it is increased or decreased. 
However, we can say that Jagged2 is present in 5 of 6 cell lines, and 7 of 8 tumor 
samples. Similar to Jagged1, it may activate Notch receptors. 
Dll1 is expressed by 5 of 6 cell lines, but negative in 75% (6/8) of tumor 
samples. In a study, it was shown that Dll1 was upregulated upon Ras 
overexpression, which also increases Notch1 expression. So, Dll1 may be involved 
in tumorigenesis upon Notch1 activation (Weijzen et al., 2002). However, our results 
are not confirmed by this study that it was expected to be upregulated or at least 
expressed in tumors. It is possible that Dll1 upregulation in the other study is related 
to overexpression of Ras, and does not occur under physiological conditions, like 
human tumor samples.      
Dll3 is not expressed by two of the cell lines and one of the tumors. There is a 
decrease in 62.5% (5/8) of tumors, but in vitro results do not support this 
observation. Dll3 mutations are found in Spondylocostal Dysostosis, which is 
characterized by developmental defects, but not reported in cancers. So, we can say 
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that Dll3 has potential to activate Notch signaling since its expression is positive in 
breast cancer cell lines and tumor samples.     
Notch3 expression is not detectable in hTERT-HME1, but it is expressed 
strongly in all of the six cell lines and 75% (6/8) of tumor samples. Notch1 and 
Notch4 are mostly studied in breast cancer, however Notch3 expression was not 
identified before. In this study, it was shown that Notch3 expression is upregulated in 
breast cancer cell lines and tumors. The next question should be whether Notch3 is 
active. Jagged1-Notch3 interactions were shown to be important in vascular smooth 
muscle cells that some of the Notch3 mutations decrease Jagged1 interaction in 
CADASIL (Joutel et al., 2004). In addition Dll1 was shown to activate Notch3 in T-
cell development (Maekawa et al., 2003). So, Jagged1 and Dll1 can bind and activate 
Notch3. Dll1 is expressed by 5 of 6 breast cancer cell lines, but negative in 75% of 
tumor samples. So, Dll1 may activate Notch3 in most of the cell lines but not in 
tumors. However Jagged1 is strongly expressed by all of the cell lines and tumor 
samples. Hence, Notch3 may be activated by Jagged1 in the breast cancer cell lines 
and tumors.  
Knockout mice studies shows that Notch3 does not have a critical role in 
development that Notch3 null mice have no apparent phenotype (Krebs et al., 2003). 
Most probably its function is compensated by other Notch receptors during 
development. Mutations found in CADASIL patients represent the possible role of 
Notch3 in vascular smooth muscle cells in brain (Joutel et al., 1997). Notch3 
activation was also shown to upregulate c-FLIP, which inhibits Fas ligand induced 
apoptosis in vascular smooth muscle cells (Wang et al., 2002). The data about 
Notch3 activity in cancer is not as detailed as other Notch receptors. Notch3 
expression is detected in neuroblastoma cell lines and overexpression is frequently 
observed in NSCLC (Pahlman et al., 2004; Collins et al., 2004). Transgenic mice 
expressing Notch3 NICD was shown to induce T-cell leukemia (Bellavia et al., 
2003). Notch3 functions as an oncogene in these cancer types. Similarly, its 
activation may contribute to human breast cancer as well. The upregulation of 
Notch3 in mammospheres represents its activity in putative breast stem cells (Dontu 
et al., 2003b). Together with the overexpression of Notch3 in breast cancer cell lines 
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and 75% of tumor samples presented in this study, we can conclude that Notch3 
activation is involved in human breast tumorigenesis. Upregulation of Notch3 in 
putative breast stem cells fits to the cancer stem cell hypothesis, which is abnormal 
Notch activity in breast stem cells induces the maintenance of stem cell properties 
and inhibits differentiation, which will promote tumor formation.   
Notch4 and Dll4 RT-PCR reactions did not give any positive results in cell 
lines. The reason may be that all cell lines I used are negative for the expression of 
both genes. Since Notch4 and Dll4 were shown to be important in vascular 
endothelial cells, it may not be expressed by mammary epithelial cell lines. However, 
I could not use a positive control that certainly expresses Notch4 or Dll4. So, the 
other possibility is that RT-PCR reaction did not work due to a problem, most 
probably related to the primers.  
The RT-PCR results show that both cell lines and tumor samples express at 
least one of the three Notch receptors. They also express at least one of the Dll 
ligands, except T-44, and one of the Jagged ligands. All of the samples have receptor 
and ligand, so theoretically have capacity to activate Notch signaling. However RT-
PCR represents the expression at RNA level and the presence of receptors and 
ligands should be confirmed at protein level. Even if proteins exist, the receptors 
should be transported to the membrane and processed properly to be active.  
As a next step it was decided to test Notch receptors’ and ligands’ expression 
at protein level by western blotting and localization by immunofluoresence. 
However, the antibodies ordered from Santa-Cruz Biotechnolgy, did not work well. 
Polyclonal antibodies gave too many non-specific bands in western blotting. Notch2 
and Notch3 staining in immunofluoresence gave positive results at a high primary 
antibody dilution (1:10) in MCF-7 cell line, but the specificity of the signal was not 
satisfying. Western blotting and immunofluoresence experiments should be repeated 
with different, preferably monoclonal antibodies. Antibodies raised against active 
Notch receptors, NICD, may be used to directly determine the presence of active 
Notch. In addition, higher number tumor tissues with their normal counterparts 
should be used to confirm these results, and see Notch3 expression status in normal 
breast tissue. 
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The activity of Notch3 in cancer cell lines and tumor samples should be 
confirmed. Reporter assays detecting the CSL transcriptional activation could be 
designed to examine Notch3. However, Notch signaling does not have an enzymatic 
amplification step. Activation is achieved by a few molecules, which makes the 
detection of reporter signal harder. Localization of the intracellular domain of 
Notch3 may reflect the activity of the receptor. Localization in membrane reflects the 
inactivity, while localization in nucleus indicates the active Notch3. Antibodies 
specific to intracellular domain of Notch3 should be used for immunofluoresence 
experiments.    
Functional studies should be designed in order to identify the role of Notch3 
in breast cancer. Knockdown of Notch3 by RNAi technique in a cell line strongly 
expressing Notch3, may be used to observe the phenotypic and expression profile 
changes in the absence of Notch3. hTERT-HME1, which does not express Notch3 
can be transfected with activated Notch3. Expression profile of main cell cycle 
regulatory genes; Notch target genes including cyclinD1, ERBB2, and p21; and 
phenotype should be compared in wild-type and Notch3 transfected hTERT-HME1. 
Notch3 transfected hTERT-HME1 is expected to show transformed cell line 
phenotype like growth on soft agar and tumor formation in mice. 
Other components of the signaling may also affect the activity of Notch3. For 
example, glycosylation and three proteolytic cleavages are critical in Notch activity. 
Any deficiency in the enzymes performing these steps, like Fringe, Furin protease, 
TACE or presenilins, can inhibit Notch activation. So, further expression and 
functional analysis of these enzymes may help us to comment on Notch activation in 
breast cancer. MAML coactivators are also important in initiation of transcription 
upon Notch activation. It was shown that dominant negative MAML1 could inhibit 
Notch signaling in leukemia cells transformed with activated Notch1, and increased 
MAML2 activity due to a translocation induces mucoepidermoid carcinoma (Wu and 
Griffin, 2004). MAML transcriptional coactivators may be important in Notch 
signaling activation in breast cancer as well. So, the expression status of MAML may 
be investigated in breast cancer cell lines and tumor samples.  
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It was shown that Notch signaling can activate apoptosis by a p53 dependent 
pathway in neuronal progenitor cells (Yang et al., 2004). All of the breast cancer cell 
lines used in this study have mutated p53, except MCF 7, which has wild type form. 
There is no correlation between p53 status of cell lines and the expression of Notch 
receptors and ligands. The induction of p53 dependent apoptosis by Notch signaling 
may be specific to neuronal tissue. Induction of apoptosis by Notch signaling is not 
expected in these cell lines because Notch most probably behaves like an oncogene 
in breast tissue. However, the p53 expression status should be checked in human 
breast tumor samples to observe if any correlation exists.   
An important target gene of Notch signaling is ERBB2, which has a CSL 
binding site at the promoter and shown to be upregulated by Notch signaling (Chen 
et al., 1997). Induction of ERBB2 may also contribute to Notch induced 
tumorigenesis in breast. Five of the tumor samples, T-29, T-43, T-44, T-47 and T-59 
are ERBB positive, and two tumors, T-57 and T-94, are ERBB negative. However, 
there is no correlation between ERBB status and expression of Notch receptors and 
ligands. The number of tumor samples should be increased to investigate any 
correlation between ERBB2 expression and Notch activity. Cell lines may also be 
examined for ERBB2 induction. In addition, all Notch3 expressing tumors are 
invasive ductal carcinoma samples, while two negative tumors are mucinous 
carcinoma and mixed invasive ductal carcinoma and invasive lobular carcinoma. So, 
Notch3 expression may be specific for invasive ductal carcinoma type of breast 
cancer, however; sample size should be increased in order to investigate correlation 
between Notch3 expression and specific types of breast cancer.  
Most of the studies focused on Notch1 and Notch4 in breast cancer. Their 
significant importance comes from the MMTV integration, and resulted activation in 
mouse mammary tumorigenesis. Upregulation in expression of two receptors in a 
group of DCIS samples and Notch4 expression in some of the breast cancer cell lines 
were detected before (Imatani and Callahan, 2000; Siziopikou et al., 2002). However 
there is no complete data about the expression status of all Notch receptors and 
ligands in human breast cancer cell lines and tumors. I investigated expression status 
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of all Notch receptors and ligands in six human breast cancer cell lines and eight 
breast tumor samples.  
In this study, or the first time, Notch3 expression was found to be 
significantly upregulated in breast cancer cell lines and tumors. Since, Notch3 may 
have a function in breast stem cell maintenance, its activation may cause breast cells 
to be arrested at a stem cell like phenotype, gain advantage to accumulate mutations 
and form tumors. Targeting the proliferating cells only and reducing the size of 
tumor by classical therapeutic applications cannot cure the cancer and prevent 
recursion of the disease as long as the cancer stem cells exist. It would be worthy to 
further analyze Notch3 activity in breast cancer in order to establish a relation 
between breast stem cells and tumorigenesis, which may mediate generation of novel 
therapeutic approaches.        
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